


PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

WEICKMANN WEICKMANN HUBER LISKA
PRECHTEL BÖHM WEISS TIESMEYER
HERZOG RUTTENSBERGER JORDAN
Kopernikusstrasse 9
D-81679 München
ALLEMAGNE



NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)

Date of mailing
(day/month/year) 29.03.2001

Applicant's or agent's file reference
19290P WO

IMPORTANT NOTIFICATION

International application No.
PCT/EP99/09440

International filing date (day/month/year)
03/12/1999

Priority date (day/month/year)
03/12/1998

Applicant
MAX-PLANCK-GESELLSCHAFT...et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

 European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Guerin, A

Tel. +49 89 2399-8061




PATENT COOPERATION TREAT

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 19290P WO		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP99/09440	International filing date (day/month/year) 03/12/1999	Priority date (day/month/year) 03/12/1998	
International Patent Classification (IPC) or national classification and IPC C12N15/12			
Applicant MAX-PLANCK-GESELLSCHAFT...et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 10 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 5 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none">I <input checked="" type="checkbox"/> Basis of the reportII <input type="checkbox"/> PriorityIII <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicabilityIV <input type="checkbox"/> Lack of unity of inventionV <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statementVI <input type="checkbox"/> Certain documents citedVII <input type="checkbox"/> Certain defects in the international applicationVIII <input checked="" type="checkbox"/> Certain observations on the international application			
Date of submission of the demand 18/06/2000		Date of completion of this report 29.03.2001	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer Vix, O Telephone No. +49 89 2399 7326	



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/09440

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

Description, pages:

1-51 as originally filed

Claims, No.:

1-40 with telefax of 14/12/2000

Drawings, sheets:

1/14-14/14 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/09440

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 24-28, 29-36.

because:

☒ the said international application, or the said claims Nos. 24-28 relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 29-36.

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims 10-14, 17-18 22-23

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/09440

	No:	Claims	1-9,15-16,19-21,37-40
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-23,37-40
Industrial applicability (IA)	Yes:	Claims	1-23,37-40
	No:	Claims	

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/09440

Reference is made to the following documents:

- D1: EP-A-0 614 978 (ROUSSEL-UCLAF) 14 September 1994 (1994-09-14)
D2: US-A-5 623 053 (LOUIS N. GASTINEL ET AL.) 22 April 1997 (1997-04-22)
D3: WO 95 09002 A (UNIVERSITY OF PENNSYLVANIA) 6 April 1995 (1995-04-06)
D4: EP-A-0 791 653 (SCHERING BIOTECH CORPORATION) 27 August 1997 (1997-08-27)
D5: JÉRÔME GALON ET AL.: 'Ligands and biological activities of soluble Fcγ receptors' IMMUNOLOGY LETTERS, vol. 44, January 1995 (1995-01), pages 175-181,
D6: EP-A-0 321 842 (KISHIMOTO, TADAMITSU) 28 June 1989 (1989-06-28)
D7: JANET M. ALLEN ET AL.: 'Isolation and expression of functional high-affinity Fc receptor complementary DNAs' JOURNAL OF CRYSTAL GROWTH, vol. 93, no. 1-4, November 1988 (1988-11) - December 1988 (1988-12), pages 378-381, Amsterdam, NL
D8: WILHELM P. BURMEISTER ET AL.: 'Crystal structure at 2.2Å resolution of the MHC-related neonatal Fc receptor' NATURE, vol. 372, no. 6504, 24 November 1994 (1994-11-24), pages 336-343, LONDON GB
D9: WO 99 05271 A (GOULD, HANNAH ET AL.) 4 February 1999 (1999-02-04)
D10 FR-A-2 739 560 (ROUSSEL UCLAF) 11 April 1997 (1997-04-11)

Document cited by the examiner:

- D11 Grueninger-Leitch F, D'Arcy A, D'Arcy B, Chene C., 'Deglycosylation of proteins for crystallization using recombinant fusion protein glycosidases.', Protein Sci 1996 Dec;5(12):2617-22

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. Concerning claims 24-28 applicant's attention is drawn to Rule 67(v) PCT. Claims 24-28 refer to a crystalline preparation for the generation of FcR crystal structure data. The subject-matter of claims 24-28 dealing with the presentation of crystal structure data and use thereof is not regarded as patentable invention within the meaning of

Rule 67 (v) PCT since it only relates to a presentation of information (protein structure coordinates) stored on a computer, including electronic databases and paper. The applicant is, however, requested to note that it may be possible to obtain alternative protection in the form of a copyright.

2. No examination has been performed for the subject-matter of claims 29-36 because of non-establishment of search report for said claims.

Relating to this, a meaningful opinion with regard to novelty of claims 29-36 cannot be established because it is not possible to determine if any of the presently known substances is falling under the terms of these claims. Besides it is noted, that the compounds of claims 29-34, and use their in claims 35-36, are not rendered novel just because of the fact that they have been identified by using a three-dimensional structure, e.g. such compounds can already exist. (Apart from this, it is also not possible to establish the scope of these claims without testing all known substances, clearly an undue burden).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Priority documents have not been available at the time of establishing this preliminary opinion. The IPER has been established under the assumption of valid priority rights. Should this however not be the case, the document D9 cited in the ISR as P-document might become important.

2. Novelty (Art. 33(2) PCT)

The application relates to recombinant soluble Fc receptors (FcR) and use thereof, the FcR being characterised by the absence of transmembrane domain, signal peptide and glycosylation.

The ISR reports an abundant prior art dealing with various type of soluble human or murine FcR and their use.

Due to the broad wording of the product claims 1-5, many known FcRs mentioned might fall within the scope of said claims. Although different specific examples or

embodiments in D1-D2 and D4 are related to eukaryotic expression system, all these documents also refer to prokaryotic expression system as other possible systems (e.g. D1 page 5, or D2 column 7 line 25-32, D4 column 7 line 37-40 and column 8, line 54-59). For instance, D1 discloses a FcγRIII human soluble receptor that can be expressed in both prokaryotic or eukaryotic system (D1 page 5). As such, this soluble FcγRIII attacks novelty of present claims 1-5 because it lacks the transmembrane domain, is not glycosylated when expressed in the prokaryotic system, and does not have a signal peptide.

Consequently, claims 1-5 can be considered as lacking novelty in view of the alternatively expressed Fc receptors disclosed in D1-D2 and D4.

Furthermore, it is to be mentioned that the specific sequences SEQ ID N°:1-6 mentioned in claim 5 show a high level of identity with different sequences deposited in public databases:

- SEQ ID N°1 shows 100% identity in a 168 amino-acids overlap with FcγRI (entry number P12314)
- SEQ ID N°2 shows 100% identity in a 170 amino-acids overlap with FcγRIIa (entry number P07446)
- SEQ ID N°3 shows 100% identity in a 184 amino-acids overlap with FcγRII (entry number 000523)
- SEQ ID N°4 shows 100% identity in a 175 amino-acids overlap with FcγRII (entry number R61122)
- SEQ ID N°5 shows 99.5% identity in a 183 amino-acids overlap with FcεRI (entry number R42336)
- SEQ ID N°6 shows 100% identity in a 274 amino-acids overlap with soluble CD23 (entry number W13143).

Correspondingly, the polynucleotides coding for the above mentioned FcRs are closely related to the subject-matter of claims 6-9. Thus, novelty of claims 6-9, which are directed to recombinant nucleic acid encoding FcR contained in a prokaryotic expression system, is questionable and cannot be acknowledged.

Claims 10-14 refer to a process for the determination of the amount of antibodies of a "certain Ig class in the blood" using the sFcR in an immuno assay. No corresponding examples appear to be cited in the available prior art.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/09440

However, claims 15-16 refers to a process for the determination of the "immune status" (see also item VIII) of patients with chronic diseases of the immune system (e.g. such as AIDS or MM) using the FcR in a competitive immunoassay. The prior art describes competition immuno-assays using soluble FcR (e.g. D3 page 20, line 9-11). Moreover, D1 (page 7 line 10-15) mentions the use of ELISA techniques in order to determine the amount of soluble FcR in biological fluids in order to diagnose "FcR- related" diseases. Thus, due to the broadly defined subject-matter, novelty of claims 15-16 cannot be acknowledged.

The pharmaceutical compositions of claims 19-21 containing soluble FcR also lack novelty because the polypeptides are known to be involved in various diseases such as autoimmune disorders and are used as active ingredients in pharmaceutical compositions - insofar the prokaryotic expression system is considered (e.g see D3 or D5 for autoimmune diseases, or D10 for HIV infection prevention).

Claims 22-23 refer to a crystalline preparation of a soluble recombinant Fc receptor and the generation of crystal structure data. No other sFcR of the available prior art is dealing with this specific subject-matter. Only D8 reports the structure of another class of Fc receptor which does not belong to the immunologically active Fc receptor of the present application. D8 deals with the soluble extracellular portion of rat neonatal FcR (FcRn) which has been successfully expressed and purified - the FcRn preparation allowed the crystallization of the protein in space group C222₁ prior to its structure determination at 2.2 Å resolution. Thus, the subject matter of claims 22-23 is considered to be novel in view of the available prior art.

Claims 37-38 refer to a FcR bound to a solid phase whereas claims 39-40 use said solid phase support to adsorb immunoglobulin from different mixtures. Such claims are not novel in view of D2 which mentions such FcR attachment to a surface and the use of the attached immobilized FcR to isolate antibodies from a mixture comprising such antibodies (see D2 column 6, line 65 - col. 7, line 2). Thus said claims 37-40 are not considered to be novel in view of D2.

In summary, the subject matter of claims 1-9, 15-16, 19-21 and 37-40 is not considered to be novel. Thus, said claims do not meet the requirement of Articles 33(2)/(3) PCT.

3. Inventive step (Art. 33(3) PCT)

If at all new, the subject-matter of the claims 1-23 and 37-40 does not involve an inventive step for the following reasons.

- 3.1 The protein crystallization is a known bottle neck in 3D structure determination and needs a great amount of homogeneous biological material. Thus, the most common strategy in protein crystallography was to choose the "easiest" expression system over the more complex one. Therefore, the person of skill would choose to overexpress a protein to crystallize in a prokaryotic system, where the problems of glycosylation heterogeneity are limited (in addition, the prokaryotic system allows a high level of expression at limited cost). However, it is very often when the prokaryotic system expression does not allow a proper folding of the protein, or if the protein is not biologically active in its unglycosylated state, that the person skilled in the art would in priority select an eukaryotic expression system. In this case, the skilled person would carefully analyse the level of glycosylation of the protein expressed because it can be an important source of heterogeneity- or even hinder the interaction with different biological counterparts (if heavy glycosylation). Relating to this, in D11 the authors describe the importance of deglycosylation for the obtention of high quality protein crystals when the protein is produced in eukaryotic system.

In the present application, no examples of possible surprising effects or advantages of the prokaryotic system over the eukaryotic system has been demonstrated.

Therefore, in absence of evidence showing unknown or unexpected effects or properties of presently claimed sFcR, the presence of an inventive step cannot be acknowledged since the mere provision of sFcR produced in a prokaryotic system, using methods which are known in the art for this purpose, does not involve an inventive activity to a person skilled in the art (Art. 33(3) PCT).

Thus the subject-matter of claims 1-23 and 37-40 does not appear to be inventive over the available prior art D1-D6 describing the production and use of sFcR produced in eukaryotic expression systems. Consequently said claims do not satisfy the criterion set forth in Article 33(3) PCT.

- 3.2. Claims 10-14 relate to a process for determination of the amount of IgE or IgG

antibodies in the blood, plasma or serum of patient using ELISA. The prior art disclose various ELISA tests performed with immobilised antibodies to check the presence of Fc receptors in a media (e.g. D6, column 15). Due to the known biological function of the Fc receptor, and in view of the above mentioned existing tests, the subject-matter of claims 10-14 using the FcR to determine the presence of specific antibody (could be considered as a "mirror" ELISA test) does not appear to involve an inventive step in the sense of Art. 33(3) PCT.

- 3.3. Methods of modulating the interaction of immune complexes with Fc receptors were disclosed in D3 in order to treat diseases resulting from interaction between immune complexes and Fc receptors. Moreover, it was known that the FcRs are involved in various chronic diseases of the immune system (see also D4, column 1, line 41-51). Thus, the man skilled in the art would regard as a normal design procedure to screen substances in view of their ability to act as inhibitors of the FcR recognition in the cases where the FcR is implicated in chronic diseases such as autoimmune diseases. Thus, the subject-matter of claim 17-18 does not involve an inventive step and does not satisfy the criterion set forth in Article 33(3) PCT.

Re Item VIII

Certain observations on the international application

1. The designations "soluble Fc receptor" or "Fc γ R" and "Fc ϵ R" appearing in claims 1-4 are not suitable to clearly and unambiguously characterise a specific polypeptide. Therefore, it needs to be clarified to clearly define the subject-matter of said claims. Relating to this, applicant's attention is drawn to the fact that a polypeptide is a chemical compound which can be clearly and unambiguously characterised by its primary sequence.
2. The expression "immune status" in claim 15 is ambiguous an open to interpretation, and thus render the scope of said claims unclear (Article 6 PCT).

Fig. 1




Fig. 2





Fig. 3



PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 14 August 2000 (14.08.00)	
International application No. PCT/EP99/09440	Applicant's or agent's file reference 19290P WO
International filing date (day/month/year) 03 December 1999 (03.12.99)	Priority date (day/month/year) 03 December 1998 (03.12.98)
Applicant SONDERMANN, Peter et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

19 June 2000 (19.06.00)

☐ in a notice effecting later election filed with the International Bureau on:
2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Charlotte ENGER Telephone No.: (41-22) 338.83.38
---	---

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/705, C12N 1/21, 15/70, G01N 33/53, 33/68, A61K 38/17, C07K 17/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/32767 (43) International Publication Date: 8 June 2000 (08.06.00)</p>
<p>(21) International Application Number: PCT/EP99/09440 (22) International Filing Date: 3 December 1999 (03.12.99) (30) Priority Data: 98122969.3 3 December 1998 (03.12.98) EP (71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Hofgartenstrasse 8, D-80539 München (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): SONDERMANN, Peter [DE/DE]; Pfeuferstrasse 97, D-81373 München (DE). HUBER, Robert [DE/DE]; Schlesierstrasse 13, D-82110 Germering (DE). JAKOB, Uwe [DE/DE]; Guldeinstrasse 42, D-80339 München (DE). (74) Agents: WEICKMANN, H. et al.; Kopernikusstrasse 9, D-81679 München (DE).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: RECOMBINANT SOLUBLE Fc RECEPTORS</p>		
<p>(57) Abstract</p> <p>Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycosylation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host cells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modelling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that can be used to separate and/or enrich antibodies.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Recombinant soluble Fc receptors

Specification

5

The present invention relates to recombinant soluble Fc receptors (FcR), recombinant nucleic acids coding for such Fc receptors, host cells containing corresponding nucleic acids as well as a process for the determination of the amount of antibodies of a certain type contained in the blood, plasma or serum of a patient, a process for the determination of the immune status of patients with chronic diseases of the immune system and a process for the screening of substances in view of their ability to act as inhibitors of the recognition and binding of antibodies to the respective cellular receptors. Further, the present invention is concerned with pharmaceutical compositions containing the recombinant soluble FcRs, crystalline preparations of FcRs and FcR/Ig-complexes and especially of the use of such crystalline preparation for the generation of crystal structure data of Fc receptors as well as FcR inhibitors and pharmaceutical compositions containing such FcR inhibitors.

20

A still further subject of the present invention is a recombinant Fc receptor coupled to a solid phase, e.g. a chromatography carrier material. The use of such chromatography material, which is another subject of the present invention, lies in the absorption of immunoglobulins from a body fluid of patients or from culture supernatants of immunoglobulin producing cells.

25

Fc receptors (FcRs) play a key role in defending the human organism against infections. After pathogens have gained access to the blood circulation they are opsonized by immunoglobulins (Igs). The resulting immunocomplexes bind due to their multivalency with high avidity to FcR bearing cells leading to clustering of the FcRs, which triggers several effector functions (Metzger, H., 1992A). These include, depending on the expressed FcR type and

30

- 2 -

associated proteins, endocytosis with subsequent neutralization of the pathogens and antigen presentation, antibody-dependent cellular cytotoxicity (ADCC), secretion of mediators or the regulation of antibody production (Fridman et al, 1992; van de Winkel and Capel, 1993).

5

Specific FcRs exist for all Ig classes, the ones for IgG being the most abundant with the widest diversity. Together with the high affinity receptor for IgE (FcεRIa), FcγRI (CD64), FcγRII (CD32) and FcγRIIIa (CD16) occur as type I transmembrane proteins or in soluble forms (sFcRs) but also a glycosylphosphatidylinositol anchored form of the FcγRIII (FcγRIIIb) exists. Furthermore, FcγRs occur in various isoforms (FcγRIa, b1, b2, c; FcγRIIa1-2, b1-3, c) and alleles (FcγRIIa1-HR, -LR; FcγRIIIb-NA1, -NA2) (van de Winkel and Capel, 1993). In contrast to the overall homologous extracellular parts, the membrane spanning and the cytoplasmic domains differ. They may be deleted entirely or be of a size of 8 kDa. They may contain either a 26 amino acid immunoreceptor tyrosine-based activation motif (ITAM) as in FcγRIIa or a respective 13 amino acid inhibitory motif (ITIM) in FcγRIIb involved in signal transduction (Amigorena et al, 1992).

20 Judged by the conserved spacing of cysteins, the extracellular part of the FcRs consists of three (FcγRI, CD64) or two (FcεRI, FcγRII, CD32 and FcγRIII, CD16) Ig-like domains (10 kDa/domain) and therefore belongs to the immunoglobulin super family. These highly glycosylated receptors are homologues, and the overall identity in amino acid sequence among the FcγRs and FcεRIa exceeds 50% in their extracellular regions. Nevertheless, the affinity of FcRs to their ligands varies widely. The higher affinity of $\approx 10^8 \text{M}^{-1}$ of the FcγRI to Fc-fragment is assigned to its third domain, while the other FcγRs with two domains have an affinity to IgG varying between 10^5 and 10^7M^{-1} . The affinity of the two domain FcεRIa to IgE exceeds these values by far with a constant of 10^{10}M^{-1} (Metzger, H., 1992B). In contrast to the mentioned FcRs the low affinity receptor for IgE FcεRII represents a type transmembrane protein and shows a lower homology.

30

FcγRs are expressed in a defined pattern on all immunological active cells. FcγRI is constitutively expressed on monocytes and macrophages and can be induced on neutrophils and eosinophils. The physiological role of FcγRI is still unknown as the expression on monocytes is not vital (Ceuppens et al, 1988). The GPI anchored form of FcγRIII (FcγRIIIb) is exclusively expressed on granulocytes. Due to its missing cytoplasmic part, the signal transduction into the cell occurs solely via other transmembrane proteins like complement receptor type 3 (CR3) that can at least associate with FcγRIIIb (Zhou et al, 1993; Poo et al, 1995). FcγRIIIa is mainly expressed on monocytes and macrophages but only in conjunction with associated proteins (e.g. α- or γ-chains). FcγRII is the receptor with the widest distribution on immunocompetent cells and is mainly involved in the endocytosis of immunocomplexes.

FcγRIIa and FcγRIIb differ in their extracellular region by only 7% of the amino acid residues. Nevertheless, both forms can be distinguished by their binding characteristics to human and mouse IgG subclasses (van de Winkel and Capel, 1993) and their differing affinity to human IgGs (Sondermann et al, 1998A). The situation is rendered even more complicated by the high responder/low responder (HR/LR) polymorphism of FcγRIIa named after the ability of T cells from some individuals to respond to murine IgG1-induced mitogenesis (Tax et al, 1983). Later, it was found that the two exchanges in the amino acid sequence between the LR and the HR form modify the ability to bind human IgG2, which leads to the suggestion that at least one of them is involved in IgG binding (Hogarth et al, 1992).

In contrast to the beneficial role FcRs play in the healthy individual, they also transmit the stimulation of the immune system in allergies (FcεRIa) or autoimmune diseases. Moreover, some viruses employ FcγRs to get access to cells like HIV (Homsy et al, 1989) and Dengue (Littaua et al, 1990) or slow down the immune response by blocking FcγRs as in the case of Ebola (Yang et al, 1998) and Measles (Ravanel et al, 1997).

- 4 -

Hence, the object underlying the present invention was to provide receptors which are easy to produce and can advantageously be used for medical or diagnostic applications. Moreover, it was an object of the invention to provide soluble receptors exhibiting a binding specificity and activity which is analogous to that of the receptors occurring naturally in the human body and which, additionally, make it possible to produce crystals suitable for a structure determination.

This object is accomplished by recombinant soluble Fc receptors which consist only of the extracellular portion of the receptor and are not glycosylated. The receptors according to the present invention are therefore characterized by the absence of transmembrane domains, signal peptides and glycosylation.

Particularly preferred for the present invention are Fc γ or Fc ϵ receptors. This is because IgG and IgE molecules are characteristic for a multiplicity of diseases and conditions, so that their determination and possible ways of influencing them are of great interest. Figure 11 and 12 show an alignment of amino acid sequences of the extracellular parts of some Fc γ R and Fc ϵ RI. The FcRs according to the invention include all these sequences or parts thereof that still retain binding capacity to antibodies and/or proper crystallization.

In a particularly preferred embodiment of the invention the recombinant soluble FcR is a Fc γ RIIb receptor. Further, it is particularly preferred that the receptor be of human origin. In a particularly preferred embodiment, it contains an amino acid sequence as shown in one of SEQ ID NO:1 to SEQ ID NO:6.

According to the present invention, the preparation of the soluble Fc receptors preferably takes place in prokaryotic cells. After such expression, insoluble inclusion bodies containing the recombinant protein form in

- 5 -

prokaryotic cells, thus facilitating purification by separation of the inclusion bodies from other cell components before renaturation of the proteins contained therein takes place. The renaturation of the FcRs according to the present invention which are contained in the inclusion bodies can principally
5 take place according to known methods. The advantage of the preparation in prokaryotic cells, the production of inclusion bodies and the thus obtained recombinant soluble Fc receptors make it possible to obtain a very pure and, in particular, also very homogeneous FcR preparation. Also because of the absence of glycosylation the obtained product is of great
10 homogeneity.

Soluble Fc receptors hitherto produced by recombinant means particularly exhibited the disadvantage that a much more elaborate purification was required, since they were expressed in eukaryotic cells and, due to the
15 glycosylation which is not always uniform in eukaryotic cells, these products were also less homogeneous.

The recombinant soluble Fc receptors according to the present invention even make it possible to produce crystals suitable for use in X-ray analysis,
20 as shall be explained later on in the description of further embodiments of the invention. The FcRs of the present invention moreover exhibit practically the same activity and specificity as the receptors naturally occurring in vivo.

A further subject matter of the present invention is a recombinant nucleic
25 acid having a sequence coding for a recombinant soluble Fc receptor according to the present invention.

The nucleic acid according to the present invention may contain only the coding sequences or, additionally, vector sequences and/or, in particular,
30 expression control sequences operatively linked to the sequence encoding the recombinant FcR, like promoters, operators and the like.

- 6 -

In a particularly preferred embodiment the nucleic acid of the present invention contains a sequence as shown in one of SEQ ID NO:7 to SEQ ID NO:12. For a comparison, SEQ ID NO:13 and SEQ ID NO:14 show the respective wild type sequences coding for FcγRIIb and FcεRIa. SEQ ID NOs:15-18 show the wild type sequences for FcγRI, FcγRIIa, FcγRIII and FcεRII.

If the nucleic acid of the present invention contains vector sequences, then these are preferably sequences of one or several prokaryotic expression vectors, preferably of pET vectors. Any other known functions or components of expression vectors may also be contained in the recombinant nucleic acid according to the present invention if desired. These may, for instance, be resistance genes allowing for an effective selection of transformed host cells.

A still further subject matter of the present invention is a host cell containing a recombinant nucleic acid according to the present invention. As repeatedly mentioned above, the host cell preferably is a prokaryotic host cell, particularly an E. coli cell.

The recombinant soluble Fc receptors according to the present invention can be used for a multitude of examinations or applications because they specifically react with antibodies. In vivo, the soluble Fc receptors are powerful immunoregulators which, if present in elevated levels, result in a remarkable suppression of the immune system which leads to many partly known and partly not yet understood effects. Based on these effects, several applications of the Fc receptors according to the present invention are further subject matters of the present invention.

One such subject is a process for the determination of the amount of antibodies of a certain type in the blood or serum of a patient, which is characterized by the use of a recombinant soluble FcR according to the

- 7 -

invention in an immunoassay, and the determination of the presence of FcR-antibody complexes. Such assay allows to screen for the presence of a certain kind of antibody and allows also for the determination of the amount of antibodies present in the blood, plasma or serum of a patient.

5

Any type of immunoassay is principally suitable for the use according to the present invention, as long as the presence of FcR-antibody complexes can thereby be detected. Both ELISA (enzyme-linked immunosorbent immunoassay), particularly sandwich assays, and RIA (radio-immunoassay) are suitable, but also competitive testing methods. In a preferred embodiment of the invention where the presence and/or the amount of IgE antibodies is to be examined, an FcεR is used as recombinant soluble receptor according to the present invention. In particular, this method is suited and advantageous for determining a predisposition or manifestation of an allergy.

15

Moreover, a method is preferred in which the presence of soluble FcRs is to be determined and, if required, quantified. For such determination preferably a competitive immunoassay method is used, wherein as competition reagent a recombinant soluble receptor according to the invention is used, most preferably a recombinant FcγR. By means of this test among others the immune status of patients with chronic diseases of the immune system can be determined in a competitive immunoassay. Chronic diseases in the sense of these processes are for instance AIDS, SLE (systemic lupus erythematosus), MM (multiple myeloma) or rheumatoid arthritis, or in the case of FcεRII in B-CLL (Gordon et al., 1987), hyper IgE syndrome (Sarfati et al., 1988) or HCL (Small et al., 1990).

25

A further advantageous use of the recombinant receptor according to the present invention lies in the screening of substances in view of their ability to act as inhibitors of the recognition and binding of antibodies to the respective cellular receptors.

30

By means of modern screening techniques such as HTPS (high throughput screening) in combination with multi-well microtiter plates and automatic pipetting apparatuses it is nowadays possible to simultaneously test a multitude of substances for specific properties. As the FcRs according to the present invention can be easily produced at low cost, they can also be
5 used in such series tests by which substances having an inhibiting effect can easily be identified.

Particularly preferred is such use according to which Fc receptors according to the present invention are used to find or screen inhibitors capable of
10 inhibiting the recognition and binding of the respective antibodies to the particular receptor of interest.

A further area of application of the substances according to the invention lies in the pharmaceutical field. Hence, a further subject matter of the invention is a pharmaceutical composition comprising as active agent a recombinant soluble FcR according to the invention. According to the present invention, this pharmaceutical composition may of course comprise conventional useful carrier and auxiliary substances. Such substances are
20 known to the person of skill in the art, the mode of administration also having to be taken into account. The pharmaceutical composition of the present invention can be advantageously used for the treatment or prevention of autoimmune diseases, allergies or tumor diseases.

Soluble forms of Fc receptors such as FcγRIII mediate isotype-specific regulation of B cell growth and immunoglobulin production. In a murine model of myeloma, sFcR suppresses growth and immunoglobulin production of tumor cells (Müller et al, 1985; Roman et al, 1988; Teillaud et al, 1990). Furthermore, sFcR binds to surface IgG on cultures of human IgG-secreting myeloma cells and effects suppression of tumor cell growth and IgG
30 secretion. Prolonged exposure of these cells to sFcR results in tumor cell cytotoxicity (Hoover et al, 1995).

Also, overreactions of the immune system in allergic reactions or due to massive antigen load might be reduced by, for example, intravenous application of soluble FcR (Ierino et al, 1993).

5 Therefore, a preferred pharmaceutical composition according to the invention for use in the treatment of AIDS, rheumatoid arthritis or multiple myeloma contains a recombinant soluble Fc γ receptor and, preferably, a receptor having the amino acid sequence as shown in SEQ ID NO:1-4.

10 It was also of great interest to obtain crystal structure data of Fc receptors and/or Fc receptor/Ig complexes. On the one hand, these are a key to the understanding of molecular mechanisms in immunocomplex recognition. On the other hand, these structural data can be used to find out common features in the structures of different Fc receptors and use the knowledge
15 of the structures to generate inhibitors or identify and produce new artificial antibody receptors.

It was also of great interest to obtain information on the concrete binding sites of immunoglobulins to their respective receptors in naturally occurring
20 three-dimensional molecules. Therefrom even more precise findings on the interactions between antibody and receptor can be obtained and also on how these interactions can be modulated. In this connection modulation means either an enhancement of the interaction or a reduction leading to an inhibition by e.g. covering the binding sites on one or more parts of the
25 complex.

To obtain such crystal structure data and conformation information, a crystalline preparation of the recombinant soluble Fc receptor according to the invention is used. The recombinant soluble FcRs according to the
30 invention surprisingly can be obtained pure enough to produce crystals that give reliable X-ray structure determination data. Such crystallization was not

- 10 -

possible with the hitherto produced receptor molecules, mostly due to their lack of homogeneity.

Therefore, another embodiment of the present invention concerns a
5 crystalline preparation of an Fc receptor according to the invention. Yet
another embodiment of the present invention is a crystalline preparation of
a complex of soluble Fc receptor according to the invention together with
the related immunoglobulin Fc part. Particular preferred embodiments are
shown in the examples as well as the relevant crystal structure data. Via
10 crystal structure analysis of the crystalline preparations the exact amino
acids of the Fc receptor/Ig complexes could be detected which mediate the
coupling. These amino acids are in shown Fig 6a and 6b and the type of
binding between the individual amino acids of both molecules in the
complex is also indicated. A further embodiment of the present invention is
15 therefore the use of a crystalline preparation of a recombinant soluble Fc
receptor for the generation of crystal structure data of Fc receptors. From
this crystal structure data information about the three-dimensional structure
and the active sites for the binding of antibodies can be obtained. Especially
preferably is the use of a crystalline preparation of a complex of
20 recombinant soluble Fc receptor according to the invention and the
corresponding immunoglobulin molecule for the generation of crystal
structure data for the complexes. These data allow to determine the actual
interactions that are formed between the two molecules and allow for the
first time to obtain exact information about the interaction of the molecules
25 thereby conferring knowledge about possible sites for inhibition or
enhancement of the binding. On the basis of the information obtained from
the crystal structure data the findings necessary for effecting modulation of
the interaction between Fc receptor and immunoglobulin can be obtained.
This modulation can be range from enhancement to complete inhibition to
30 an inhibition of the binding.

- 11 -

The stated applications are merely preferred embodiments of the use of the crystal structure data. Many other applications seem possible, too.

5 Suitably, the structural data for the generation and/or identification of inhibitors or new receptors, respectively, are used in a computer-aided modelling program.

10 Particularly preferred for the present invention are the structures of FcRs or FcR:Fc-fragment complexes as exemplified in figures and examples. Such structures can be used to design inhibitors, antagonists and artificial receptor molecules.

15 Computer programs suitable for computer-aided drug design and screening are known to the person skilled in the art and generally available. They provide the possibility to examine umpteen compositions on the computer in view of their ability to bind to a certain molecule when the corresponding structure dates are entered in the computer. With the help of this possibility a great number of known chemical compositions can be examined regarding their inhibiting or antagonistic effect. The person skilled in the art merely
20 requires the crystal structure dates provided by the present invention and a commercially available screening program (Program Flexx: From the GMD-German National Research Center for Information Technology, Schloss Birlinghoven, D-53754 Sankt Augustin, Germany). A preferred embodiment of the present invention therefore is the use of the crystal structure data
25 obtained for the recombinant soluble Fc receptor according to the invention and for the complexes of recombinant soluble Fc receptor according to the invention and corresponding immunoglobulin in a computer aided modelling program for the identification and production of Fc receptor inhibitors.

30 Likewise, a further embodiment of the present invention is the use of the crystal structure data obtained for the receptors according to the invention and the receptor/immunoglobulin complexes, respectively for the

- 12 -

identification and preparation of new Fc receptors which can be used, e.g. as antagonists and competitors. The crystal structure data and the data on the amino acids involved in the binding to Fc receptors obtained therefrom can serve for example to generate mutated immunoglobulins which can also
5 be used as inhibitors. It is imaginable that mutated or chemically modified inhibitors undergo tight binding and thus effect a blocking of receptors. On the other hand, the data obtained for the binding sites of immunoglobulins can also be used for the identification and/or preparation of inhibitors for immunoglobulin molecules. Since the present invention teaches the binding
10 sites to the receptor, it is easy to effect a blocking of the binding sites with the help of relatively simple molecules. Therefore, a further subject matter of the present invention is the use of the crystal structure data obtained for the FcR/Ig complexes for the identification and/or preparation of immunoglobulin inhibitors.

15

Accordingly, still further subject matter of the present invention are FcR inhibitors which have a three-dimensional structure which is complementary to the recombinant soluble FcR according to the invention and inhibit the binding of antibodies to FcRs.

20

Another further subject of the present invention are immunoglobulin inhibitors which have a three-dimensional structure which is complementary to the immunoglobulin binding site for recombinant soluble Fc receptors according to the invention and inhibit the binding of immunoglobulins to Fc
25 receptors.

The term "complementary" is to be understood within the framework of the invention in such a way that the inhibitor molecules must be substances which are able to cover at least so many binding sites on the
30 immunoglobulin or on the Fc receptor that the binding between Fc receptor and immunoglobulin is at least decisively weakened. Covering can take place both by binding to the amino acids mediating the complex formation

- 13 -

of either component but also in such a way that at least complex formation is no longer possible, be it by sterically inhibition or by binding to adjacent amino acids, however, covering the amino acid involved in the complex binding between Fc receptor and immunoglobulin.

5

In connection with the present invention it was possible for the first time to determine the exact binding sites and the amino acids involved in the binding of the antibody and antibody receptor molecules. One is now able to design specifically binding molecules and to screen candidate compositions on the computer. This enables the selection of such compositions from a variety of possibly candidate compositions which can effect a sufficient inhibition of complex formation between Fc receptor and immunoglobulin.

15 What is important for the inhibitors of the invention is that, owing to their structure and specificity, they are capable of binding to the FcRs or immunoglobulins and thus prevent the normal binding between FcRs and the constant parts of antibodies.

20 Preferably, such FcR or IgG inhibitors are small organic molecules which can easily be administered orally. They are an interesting alternative to cortisone in the treatment of autoimmune diseases and host/graft rejections. Such a molecule would also suppress reinfection rates with certain viruses, e.g. Dengue virus where the antibody coated virus is FcγRIIb dependent internalized (Littau et al, 1990), HIV where on CD4 positive T cells an antibody enhancement of HIV infection is mediated by FcγRIII (Homsy et al, 1989), or Ebola where the virus secreted glycoprotein inhibits early neutrophil activation by blocking sFcγRIII which affects the host response to infection (Yang et al, 1998).

30

The development of inhibitors also leads to substances that interfere with the recognition of IgE by their receptors. From the modelled structure of

- 14 -

FcεRI, peptides have already been developed which inhibit mast cell degranulation in vitro. With the now available knowledge of the structures of the homologue receptors and the receptor-antibody complex in atomic detail, a new possibility for a rational drug design is opened.

5

The Fc-receptor bind between the two CH2-domains of the Fc-fragment in the so-called lower hinge region (Fig.8). The binding region of the Fc-receptor is described in Example 1 (The contact interface to IgG). The residues promoting the interaction between FcR and immunoglobulin are shown in figures 7, 10a and 10b. Thereby three interaction regions become evident (Fig.5).

10

1st region: FcR (residues 85 to 87 and residue 110) - Ig (Chain A residues 326-328)

Proline 328 of the Ig is clamped by the residues Trp 87 and 110 in a sandwich like manner. These residues are conserved among the IgG and IgE receptors as well as in the IgG and IgE. An inhibitor binding to this prominent region would strongly interfere with binding. This region is additionally attractive for inhibitor design because the exposed hydrophobic surface region comprising the residues Trp 87, Ile 85, Gly 86 of the receptors could be employed to obtain additional binding energy. The functional groups of Thr 113 and Glu 18 and Lys 19 side chains in the vicinity may contribute especially to specific inhibitor binding.

20

2nd region: FcR (residues 126-132 and residues 155-158) - Ig (Chain A and Chain B residues 234-239)

25

The amino terminal residues 234-239 of both Ig chains are recognised differently by the FcR, thereby breaking the 2-fold symmetry of the Fc fragment.

30

This residues of Fc-fragment chain A are in contact with residues Val 155 - Lys 158 of the receptor and the same residues from Fc-fragment chain B with receptor residues Gly 126 - His 132. This region shows the most

differences in the sequence alignment of the receptors as well as the immunoglobulins and should therefore be involved in specificity generation. This deep cleft between the Fc-fragment chains is well suited for inhibitor design and would be the site of choice for the development of inhibitors when issues of specificity are concerned.

3rd region: FcR (residues 117, 126 and 129-132) - Ig (Chain B residues 264-265 and residues 296-297)

This binding region is characterised by a clustering of amino acid residues carrying functional groups in their side chains, that might be employed in various ways for inhibitor design on the receptor and the Ig side of the contact.

Molecules that interact with one or more of the above described regions, and are designed or screened explicitly for exploiting the knowledge of binding sites are considered as inhibitors according to the invention.

Further subject matters of the present invention are pharmaceutical compositions containing as active agent an FcR inhibitor or an immunoglobulin inhibitor as mentioned above. Such pharmaceutical compositions may, for example, be used in the treatment or prevention of diseases which are due to overreactions or faulty reactions of the immune system, preferably the treatment or prevention of allergies, autoimmune diseases or anaphylactic shock.

A further subject of the present invention is the sFcR according to the invention, bound to a solid phase. Such heterogeneous receptors can be used for immunoassays or other applications where the receptor in an immobilized form can be used beneficially.

In a preferred embodiment of the invention the solid phase is a chromatography carrier material onto which the Fc receptor is fixed, e.g.

- 16 -

sepharose, dextran sulfate etc. Such chromatography materials with Fc receptors bound thereto can beneficially be used for the adsorption of immunoglobulins from the blood, plasma or serum of patients or from the culture supernatant of immunoglobulin producing cells (meaning
5 concentration, enrichment and purification of antibodies).

On the one hand, the antibodies bound to the chromatography material can be eluted and, for example, the immune status of a patient can thereby be determined. On the other hand, antibodies from the blood of a patient can
10 thereby be enriched before carrying out further tests, which is a further preferred embodiment of the present invention. In many cases it is difficult to conduct diagnostic assays using blood samples if the latter contains only a very small number of the antibodies to be identified. By means of a concentration using a specific chromatographic column with Fc receptors
15 according to the present invention, antibodies of interest can easily be concentrated and separated from many other substances which might disturb the test.

Basically, it is also possible to use a chromatography material according to
20 the present invention in an extracorporeal perfusion system for lavage of the blood in case of certain diseases where the removal of antibodies plays a crucial role.

It is, however, also possible to use another material as solid phase to which
25 the soluble Fc receptor according to the invention is coupled, e.g. microtiter plates or small reaction vessels to the walls of which Fc receptors are bound either directly or indirectly. Such solid phases and vessels can be particularly important for diagnostic methods, as they enable screening by using immunoassays e.g. for detecting the presence of certain
30 immunoglobulins in patients' blood or other body fluids.

To sum up, the recombinant soluble Fc receptors provided by the present invention as well as the corresponding structure determination of crystalline

preparations of these receptors and of crystalline complexes of receptors and immunoglobulins enable for the first time to perform a rational drug design, wherefrom it is possible to modulate the interaction between immunoglobulins and Fc receptors on cells or soluble receptors. Such a modulation is preferably an inhibition, whereby the inhibition of the formation of a complex from IgG and Fc receptor takes place by covering and preferably by binding of inhibitor molecules to the Fc receptor or the immunoglobulin. There are various medical applications for such modulating drugs and in particular of inhibitors and only few of these applications have been exemplary mentioned within the framework of the present specification. This can and should by no means exclude the applicability of such molecules which have been designed or screened on the basis of the findings about the molecular structure or FcR/Ig complexes disclosed herein for the treatment or prevention of other health disturbances.

The following Examples are to further illustrate the invention in conjunction with the Figures.

Example 1

shFcγRIIb (soluble human FcγRIIb)

1.1 Cloning and Expression

The cDNA of human FcγRIIb2 (Engelhardt et al, 1990) was modified using mutagenous PCR (Dulau et al, 1989). Therefore, a forward primer was used for the introduction of a new start methionine after the cleavage site of the signal peptide within a *Nco*I site (5'-AAT AGA ATT CCA TGG GGA CAC CTG CAG CTC CC-3') while the reverse primer introduced a stop codon between the putative extracellular part and the transmembrane region followed by a *Sa*I site (5' CCC AGT GTC GAC AGC CTA AAT GAT CCC C-3'). The PCR product was digested with *Nco*I and *Sa*I, cloned into a pET11d expression vector (Novagen) and the proposed sequence was

confirmed. The final construct was propagated in BL21(DE3) (Grodberg and Dunn, 1988). For the overexpression of FcγRIIb a single colony of the transformed bacteria was inoculated in 5ml LB medium containing 100 μg ampicillin per ml (LB-Amp100) and incubated overnight at 37°C. The culture was diluted 200-fold in LB-Amp100 and incubation was continued until an OD600 of 0.7-0.9 was achieved. The overproduction of the protein was induced by adding IPTG to a final concentration of 1 mM. After a growing period of 4 hours the cells were harvested by centrifugation (30 min, 4000 x g) and resuspended in sonification buffer (30 mM sodium phosphate, 300 mM sodium chloride, 0.02% sodium azide, pH 7.8). After addition of 0.1 mg lysozyme per ml suspension and incubation for 30 min at room temperature the sonification was performed on ice (Branson Sonifier, Danbury, CT; Macrotip, 90% output, 80% interval, 15 min). The suspension was centrifuged (30 min, 30,000 x g) and resuspended with a Dounce homogenizer in sonification buffer containing 0.5% LDAO. The centrifugation step and resuspension in LDAO containing buffer was repeated once before this procedure was repeated twice without LDAO. The purified inclusion bodies were stored at 4°C.

1.2 Refolding and purification of soluble human FcγRIIb (shFcγRIIb)

The purified inclusion bodies were dissolved to a protein concentration of 10 mg/ml in 6 M guanidine chloride, 100 mM 2-mercaptoethanol and separated from the insoluble matter by centrifugation. The refolding was achieved by rapid dilution. Therefore, one ml of the inclusion body solution was dropped under stirring within 15 hours into 400 ml of the refolding buffer (0.1 M TRIS/HCl, 1.4 M arginine, 150 mM sodium chloride, 5 mM GSH, 0.5 mM GSSG, 0.1 mM PMSF, 0.02% sodium azide, pH 8.5, 4°C). Afterwards, the mixture was stirred for 2-3 days until the concentration of free thiol groups was reduced to 1 mM by air oxidation as measured according to Ellman (Ellman, 1959). The solution was dialyzed against PBS and sterile filtered before it was concentrated 10-fold in a stirring cell

equipped with a 3kD MWCO ultrafiltration membrane. The protein solution was applied to a hlgG sepharose column (50 mg hlgG per ml sepharose 4B). Unbound protein was washed out with 50 mM TRIS pH 8.0 before elution of FcγRIIb by pH jump (150 mM sodium chloride, 100 mM glycine, 0.02% sodium azide, pH 3.0). The eluate was immediately neutralized with 1 M TRIS pH 8.0. The FcγRIIb containing solution was concentrated and subjected to gel filtration on a Superdex-75 column equilibrated with crystallization buffer (2 mM MOPS 150 mM sodium chloride, 0.02% sodium azide pH 7.0). The fractions containing FcγRIIb were pooled, concentrated to 7 mg/ml and stored at -20°C.

1.3 Equilibrium gel filtration experiments

A Superdex75 column was connected to FPLC and equilibrated with PBS containing 10 μg shFcRIIb per ml. Human Fc fragment was solved to a concentration of 1 μg/10 μl in the equilibration buffer and injected. The resulting chromatogram yielded a positive peak comprising the complex of the shFcγRIIb and the Fc fragment while the negative peak represents the lack of receptor consumed from the running buffer for complex formation.

1.4 Crystallization and data collection

Initial crystallization trials employing a 96 condition sparse matrix screen (Jancarik and Kim, 1991) were performed in sitting drops at 20°C using the vapor diffusion method. Occuring crystals were improved by changing the pH as well as the salt, precipitant and additive concentration. Diffraction data from suitable crystals was collected on an image plate system (MAR research) using graphite monochromated CuK_α radiation from a RU200b rotating anode generator (Rigaku) operated at 50 kV and 100 mA. The reflections were integrated with the program MOSFLM (Leslie, 1997) and subsequently the data was scaled, reduced and truncated to obtain the

structure-factor amplitudes using routines from the CCP4 program suite (Collaborative Computational Project, 1994).

1.5 Summary of expression, purification and refolding of shFcγRIIb

5

The extracellular part of FcγRIIb was expressed in high levels under the control of a T7 promoter in the T7 RNA polymerase positive E. coli strain BL21/DE3 (Grodberg & Dunn, 1988). The protein was deposited in inclusion bodies, which were employed in the first purification step. The isolation of the inclusion bodies was started with an intense combined lysozyme/sonification procedure to open virtually all cells which would otherwise contaminate the product. The subsequent washing steps with the detergent LDAO, which has excellent properties in solving impurities but not the inclusion bodies itself already yielded a product with a purity of >90% (Fig. 1).

15

This product was used for refolding trials without further purification. The inclusion bodies were dissolved in high concentration of 2-mercaptoethanol and guanidine to ensure the shift of covalent and non-covalent aggregates to monomers. This solution was rapidly diluted with refolding buffer to minimize contacts between the unfolded protein molecules which would otherwise form aggregates. The use of arginine in the refolding buffer prevents the irreversible modification of side chains as often recognized with urea. After addition of the protein to the refolding buffer, the solution was stirred at 4 °C until the concentration of free thiol groups was reduced to 1 mM, which was absolutely necessary as earlier dialysis resulted in an inactive product. In a second purification step the dialyzed and refolded FcγRIIb was bound to immobilized hIgG to remove minor fractions of E. coli proteins and inactive receptor. The protein was eluted with a pH jump and immediately neutralized. After this affinity chromatography step shFcγRIIb is essentially pure except for a minor contamination resulting from the coeluting IgG which leached out of the matrix even after repeated use (Fig.

20

25

30

- 21 -

1). The IgG as well as receptor multimers which are not visible in the reducing SDS-PAGE could easily be removed by gel filtration. Parallel to the removal of the contaminants in this step the buffer is quantitatively exchanged. This procedure ensures a defined composition of the protein solution as even slight variations can cause irreproducibility of the crystallization attempts or even inhibit the formation of crystals. Overall 6 mg pure protein could be gained per litre E. coli culture, which is about 10 % from the FcyRIIb content of the inclusion bodies.

10 N-terminal protein sequencing revealed the identity with the expected sequence H₂N-GTPAAP without detectable contamination. ESI-MS analysis showed that the final material used in crystallization trials is homogenous with respect to size. From the primary sequence the molecular weight was calculated to 20434 Da, which corresponds to 20429 Da found by mass spectroscopy. The discrepancy lies within the error of the instrument, and no additional peak for a species containing the leading methionine is found.

The crystallization of shFcyRIIb was performed in sitting drops using the vapor diffusion method. Initial trials with a sparse matrix screen (Jancarik & Kim, 1991) resulted already in small crystalline needles. Subsequent optimization of the preliminary crystallization condition by varying precipitant, salt, their concentration and pH led to the isolation of three different crystal forms. Orthorhombic crystals grew from mixture of 1.5 μ l reservoir solution (33% PEG2000, 0.2 M sodium acetate, pH 5.4) with 3 μ l of the protein solution. They appeared within 3 days and reached their final size of approximately 80 μ m x 80 μ m x 500 μ m after one week. These crystals diffracted to 1.7 Å. Crystals could also be grown in two other space groups from reservoir solution containing 26% PEG8000, 0.2 M sodium acetate, pH 5.6, 5 mM Zn(OAc)₂, 100 mM sodium chloride (hexagonal form) and 26% PEG8000, 0.2 M NaOAc, pH 5.6, 10% (v/v) 1,4-Dioxan, 100 mM sodium chloride (tetragonal form). These crystals were

- 22 -

of suitable size for X-ray analysis but diffracted only to 2.7 Å and 3.8 Å for the tetragonal and hexagonal crystal form respectively (Table 1).

FcγRII was expressed in *E. coli* which, besides the comparatively low production costs and the availability, has several advantages especially when the glycosylation performed by mammalian cells is not necessary for the function of the protein as in the case of FcγRII where IgG binding occurs independently of carbohydrate attachment (Sondermann et al, 1998A). In *E. coli* a homogenous product can reproducibly be generated, which is in contrast to the expression in mammalian cells where batch dependent variances are often observed. In such a system the product is for several days exposed to proteases at temperatures of more than 30°C. In contrary, the expression of the protein in *E. coli* under the control of the strong T7 promoter at 37°C frequently leads to the formation of protease inaccessible inclusion bodies. A further advantage of the expression in bacteria is that the material could be considered to be free of pathogenic germs, which might derive from employed fetal calf serum or the cell line itself. In mammalian expression particular care must be taken during the purification of the target protein because potential effective hormones or growth factors might be copurified. One case where the effects of sFcγR were ascribed to a TGFβ1 contamination is already reported (Galon et al, 1995).

1.6 Purification

The purification procedure is straightforward. It consists of three steps which can easily be performed in a single day. The protein is obtained in a pure form and in high yields and could even be obtained in considerable quality without the expensive IgG affinity column. The success of such a protocol would depend on the careful preparation of the inclusion bodies, as most of the impurities can be eliminated already in the first purification step.

1.7 Characterization

The purified FcγRIIb was characterized by SDS-PAGE and isoelectric focussing as well as N-terminal sequencing and mass spectroscopy. Thus, the material can be considered pure and homogeneous with respect to its chemical composition, but the intriguing question whether the receptor is correctly folded remains to be discussed. All cysteins are paired, since no free thiol groups are detected with Ellman's test. The material is monomeric and eludes with the expected retention time in peaks of symmetrical shape from a size exclusion chromatography column. Furthermore, FcγRIIb binds to IgG sepharose, recombinant FcγRIIb from E. coli is active because it specifically binds IgG.

1.8 Crystallization

The orthorhombic crystal form of FcγRIIb diffracted X-rays to a resolution of 1.7 Å, which is a drastic improvement compared to previously reported crystals of the same molecule derived from insect cell expression (Sondermann et al, 1998A). These crystals diffracted to 2.9 Å and were of space group P3₁21. Thus, the glycosylation of the insect cell derived receptor influences the crystallization conditions. Instead of the trigonal space group, three different crystal forms are found. After a possible solution of the structure these crystal forms will help identify artificial conformations of the protein due to crystal contacts.

FcγRs do not exhibit any sequence similarity to other proteins but due to a conserved cystein spacing they are affiliated to the immunoglobulin super family. Consequently, we tried to solve its structure by molecular replacement, but extensive trials using IgG domains from a variety of molecules failed. Thus the structure of FcγRIIb has to be solved by the methods of multiple isomorphous replacement.

- 24 -

We have shown for the first time that FcγRIIb can be obtained in an active form from *E. coli*. This is the basis for crystallographic investigations that will soon, due to the already gained crystals of exceptional quality, result in the structure solution of this important molecule. The structure will provide information on the IgG binding site and provide a starting point for the knowledge based design of drugs that interfere with recognition of the ligand by its receptor. Furthermore, because of the high homology between FcγRIIb and other FcRs including FcεRIa it seems possible that these molecules can be produced in the same way, which would provide valuable material for the ongoing research.

1.9 Methods

Protein chemistry

Recombinant soluble human FcγRIIb was expressed in *E. coli*, refolded purified and crystallized as described elsewhere (Sondermann et al, 1998B). Briefly, the putative extracellular region of hFcγRIIb2 (Engelhardt et al, 1990) was overexpressed in *E. coli*. Inclusion bodies were purified by lysozyme treatment of the cells and subsequent sonification. The resulting suspension was centrifuged (30 min 30,000 x g) and washed with buffer containing 0.5% LDAO. A centrifugation step and resuspension in LDAO containing buffer was repeated once before this procedure was repeated twice without LDAO. The inclusion bodies were solved in 6 M guanidine hydrochloride and the protein was renatured as described. The dialyzed and filtrated protein solution was applied to a hIgG sepharose column and eluted by pH jump. The concentrated neutralized fractions were subjected to size-exclusion chromatography on a Superdex-75 column (26/60, Pharmacia).

Crystallization

Crystallization was performed in sitting drops at 20°C using the vapor diffusion technique. Crystallization screens were performed by changing pH,

- 25 -

salt, precipitant and additives. The final crystals used for data collection were grown in 33% PEG2000, 0.2 M sodium acetate, pH 5.4 (orthorhombic form) 26% PEG8000, 0.2 M sodium acetate, pH 5.6, 10% (v/v) 1,4-dioxane, 100 mM sodium chloride (tetragonal form), and 26%
5 PEG8000, 0.2 M sodium acetate, pH 5.6, 5mM ZN(OAc)₂, 100 mM sodium chloride (hexagonal form). The insect cell derived protein was crystallized in 32% PEG6000, 0.2 M sodium acetate, pH 5.3.

Preparation of heavy-atom derivatives

10 The heavy-atom derivatives were prepared by soaking the crystals in the crystallization buffer containing 2 mM platinum(II)-(2,2'-6,2''terpyridinium) chloride for 24 hours or 10 mM uranylchloride for 8 days.

X-ray data collection

15 Diffraction data was collected on an image plate system (MAR research) using graphite monochromated CuK_α radiation from a RU200b rotating anode generator (Rigaku) operated at 50 kV and 100 mA. The reflections were integrated with the program MOSFLM 5.50 (Leslie, 1997) and subsequently the data was scaled and truncated to obtain the
20 structure-factor amplitudes using routines from the CCP4 program suite (Collaborative Computational Project, 1994).

Structure determination

The structure was solved with the standard procedures of the MIR method.
25 From the large number of soaks carried out with different heavy-atom components only the two compounds yielded interpretable Patterson maps. The heavy-atom positions for each derivative were determined from difference Patterson maps and initial phases were calculated. Cross-phased difference Fourier maps were used to confirm heavy atom positions and
30 establish a common origin for the derivatives. Anomalous data were included to discriminate between the enantiomers. The heavy atom parameters were further refined with the program MLPHARE from the CCP4

- 26 -

package leading to the statistics compiled in Table 2. An electron-density map was calculated to a resolution of 2.1 Å and the phases were improved further by solvent flattening and histogram matching with the program DM from the CCP4 suite. The resulting electron density map was of sufficient quality to build most of the amino acid residues. Model building was performed with O (Jones et al, 1991) on an Indigo2 work station (Silicon Graphics Incorporation). The structure refinement was done with XPLOR (Brünger et al, 1987) by gradually increasing the resolution to 1.7 Å using the parameter set of Engh and Huber (Engh & Huber, 1991). When the structure was complete after several rounds of model building and individual restraint B-factors refinement ($R_{\text{fac}} = 29\%$ / $R_{\text{Free}} = 36\%$), 150 water molecules were built into the electron density when a Fo-Fc map contoured at 3.5 σ coincided with well defined electron density of a 2Fo-Fc map contoured at 1 σ . The resulting refinement statistic is shown in Table 3.

1.10 Structure determination

The crystal structure of recombinant soluble human FcγRIIb was solved by multiple isomorphous replacement (MIR) to 1.7 Å resolution, since a structure solution by molecular replacement with isolated domains of the Fc fragment from human IgG1 (Huber et al, 1976, PDB entry 1fc1; Deisenhofer, 1981) failed. The putative extracellular part of the receptor (amino acid residues 1-187 as depicted in SEQ ID NO:2) was used for crystallization trials (Sondermann et al, 1998B) while the model contains the residues 5-176 as the termini are flexible and not traceable into the electron density. Additionally, the model contains 150 water molecules and the refinement statistics are summarized in Table 2. The structure contains a cis proline at position 11. None of the main chain torsion angles is located in disallowed regions of the Ramachandran plot. The fully refined model was used to solve the structure of the same protein in crystals of space group P4₂2₁2 and of the glycosylated form derived from insect cells in crystals of space group P3₁21 (Table 2).

- 27 -

The polypeptide chain of FcγRIIb folds into two Ig-like domains as expected from its affiliation with the immunoglobulin super family. Each domain consists of two beta sheets that are arranged in a sandwich with the conserved disulfide bridge connecting strands B and F on the opposing sheets (Fig. 3). Three anti-parallel β-strands (A1, B, E) oppose a sheet of 5 β-strands (C', C, F, G, A2), whereby strand A1 leaves the 3-stranded β-sheet and crosses over to the 4-stranded anti-parallel sheet adding the short parallel 5th strand A2. The arrangement of secondary structure elements as well as their connectivity is identical in both domains of the FcγRIIb and a rigid body fit of one domain onto the other revealed a r.m.s. distance of 1.29 Å of 67 matching Cα atoms.

The domains are arranged nearly perpendicularly to each other enclosing an angle of 70 degrees between their long axes forming a heart-shaped overall structure. This arrangement results in an extensive contact region between the domains (Fig. 4). Residues from strand A2 and from the segment linking A2 and A1 of the N-terminal domain intermesh with residues of strands A1 and B from the C-terminal domain. This region is tightly packed and the interaction is strengthened by several hydrogen bonds resulting in a rigid arrangement. This is confirmed by the conservation of the structure in three different space groups. In orthorhombic, tetragonal and hexagonal (insect cell derived) crystal forms a deviation of less than 2° in the interdomain angle is found.

1.11 Overall structures

The structure of recombinant human FcγRIIb derived from E.coli was solved by MIR to 1.7 Å resolution from orthorhombic crystals. An essentially identical structure is found in tetragonal and with protein derived from insect cells in hexagonal crystals. In all three structures the last nine residues of the polypeptide chain were found disordered. The flexibility of the C-terminal linker region between the structured core of the molecule and

- 28 -

the transmembrane part may be functionally relevant to allow some reorientation of the receptor to enhance the recognition of the Fc parts in immunocomplexes.

5 1.12 Homologue receptors

The Ig domains found in the Ig super family of proteins are characterized by a beta sandwich structure with a conserved disulfide bridge connecting two strands of the opposing sheets. The typical arrangement of 3 and 4 anti
10 parallel beta strands that form a sandwich as found in FcγRIIb occurs also in the T cell receptor, Fc fragment, CD4 or the Fab fragment. A structural alignment of the individual Ig domains of these molecules with the two domains of FcγRIIb shows a common, closely related structure. The relative arrangement of the domains, however, is not related in these molecules and
15 covers a broad sector. Despite the structural similarity between Ig domains from different molecules and the strikingly low r.m.s. deviation of Cα atoms that result when the two domains of FcγRII are superimposed, no significant sequence similarity is found (Figs. 5a and 5b). A structure-based sequence alignment shows a conserved hydrophobicity pattern along the sequence
20 of the domains, together with, beside the cysteins, only few identical amino acid residues. We first prepared a structure-based alignment of the two C-terminal domains of the IgG1 heavy chain and the FcγRIIb and added the sequences of the other related FcγR and the FcεRIa domains. This shows that the sequences of the three domain FcγRI and the two domain receptors
25 are compatible with the hydrophobicity pattern of Ig domains and several conserved amino acid residues are revealed. Firstly, the different domains of an FcR are more related to each other than to Ig domains from other molecules of the Ig super family. Secondly, the N-terminal domains of the receptors relate to each other as the second domains do. Thirdly, the
30 sequence of the third domain of FcγRI shows features from both groups of domains. Taken together, we confirm the affiliation of the FcRs to the Ig super family and speculate that all FcR-domains originate from a common

ancestor, an ancient one domain receptor that acquired a second domain by gene duplication. Further divergent development of such a two domain receptor resulted in the present diversity, including FcγRI that acquired a third domain.

5

Conservation of these amino acid residues that contribute to the interdomain contact in FcγRIIb in the alignment are a hint to a similar domain arrangement in different receptors. In Table 4 the residues contributing with their side chains to the interdomain contact (Fig. 4) are compiled for FcγRIIb together with the corresponding amino acid residues in other receptors according to the structure-based sequence alignment of Fig. 5b. Except for Asn15, which is not conserved between the FcRs, the involved residues are identical or conservatively replaced providing strong support for a similar structure and domain arrangement in all FcRs.

15

1.13 The contact interface to IgG

Limited information about the interactions of FcRs with their ligands is available from mutagenesis studies (Hogarth et al, 1992; Hulett et al, 1994; Hulett et al, 1995). By systematically exchanging loops between the β-strands of FcγRIIa for FcεRIa amino acid residues the B/C, C'/E and F/G loops of the C-terminal domain were evaluated as important for ligand binding (Fig. 3, Fig. 5b). In the structure model these loops are adjacent and freely accessible to the potential ligand. Additionally, most of the amino acid residues in these loops were exchanged for alanines by single site mutations which resulted in a drastic alteration of the affinity of FcγRIIa to dimeric human IgG1. Also, the single amino acid exchange Arg 131 to His in the C-terminal domain (C'/E loop) in the high responder/low responder polymorphism, which alters the affinity of the FcγRIIa to murine IgG1, points to that region. Thus, the amino acid residues in this area are either important for ligand binding or the structural integrity of that region. Here, the structure shows a clustering of the hydrophobic amino acid residues Pro

30

- 30 -

114, Leu 115 and Val 116 in the neighbourhood of Tyr 157. This patch is separated from the region Leu 159, Phe 121 and Phe 129 by the positively charged amino acid residues Arg 131 and Lys 117 which protrude from the core structure (Fig. 5b).

5

1.14 Glycosylation

In the sequence of FcγRIIb three potential N-glycosylation sites are found. All three sites are on the surface of the molecule and are accessible. They are located in the E/F loops (N61 and N142) of both domains and on strand E (N135) of the C-terminal domain (Fig. 3, Fig. 6). Since the material used for the solution of this structure was obtained from *E. coli*, it does not contain carbohydrates, while the FcRs isolated from mammalian cells are highly glycosylated. The three potential glycosylation sites are located rather far from the putative IgG binding region, and non-glycosylated FcγRIIb binds human IgG, suggesting a minor role of glycosylation in binding. This was confirmed by the structure of the FcγRIIb produced in insect cells which is glycosylated (Sondermann et al, 1998A). Except for a 2° change of the interdomain angle possibly due to different crystal contacts, no differences between the glycosylated and unglycosylated protein structures were found. The three glycosylation sites are only optionally used as shown by SDS-PAGE where the material appears in 4 bands. No additional electron density for those sugars was found a consequence of chemical and structural heterogeneity.

25

Example 2

shFcγRIIa (soluble human FcγRIIa)

The procedures were performed according to example 1 except for the indicated changes:

30

2.1 Cloning and Expression

shFcγRIIa was generated by mutating the respective wild-type cDNA (Stengelin et al., 1988) and expressed according to example 1 with the mutagenous primers listed in table 5. For the expression of the protein a pET22b + vector was chosen.

2.2 Refolding and purification

shFcγRIIa was refolded according to example 1 with the respective refolding buffer listed in table 6.

2.3 Crystallisation

shFcγRIIa was crystallised as described under conditions indicated in table 7.

2.4 Structure determination

The structure was solved with the method of isomorphous replacement with shFcγRIIb as search model.

Example 3

shFcγRIII (soluble human FcγRIII)

The procedure was performed according to example 1 except for the indicated changes:

3.1 Cloning and Expression

shFcγRIII was generated by mutating the respective wild-type cDNA (Simmons & Seed, 1988) and expressed according to example 1 with the mutagenous primers listed in table 5. For the expression of the protein a pET22b + vector was chosen.

3.2 Refolding and purification

shFcγRIII was refolded according to example 1 with the respective refolding buffer listed in table 6.

5 3.3 Crystallisation

shFcγRIII was crystallised as described under conditions indicated in table 7.

3.4 Structure determination

10 The structure was solved with the method of isomorphous replacement with shFcγRIIb as search model.

3.5 Crystallisation of a shFcγRIII:hFc1 complex

hIgG1 derived from the serum of a myeloma patient was used to prepare
15 Fc-fragments (hFc1) by digestion with plasmin (Deisenhofer et al., 1976).
The resulting Fc-fragments were separated from the Fab-fragments by
protein A chromatography. Partially digested hIgG was removed by size
exclusion chromatography with MBS (2mM MOPS, 150mM NaCl, 0.02%
sodium azide, pH 7.0) as running buffer. Equimolar amounts of hFc1 and
20 shFcγRIII were mixed and diluted with MBS to a concentration of 10mg/ml.
The complex was crystallised as described under conditions indicated in
table 5.

Example 4

25 shFcεRII (soluble human FcεRII)

The procedure was performed according to example 1 except for the indicated changes:

30 4.1 Cloning and Expression

FcεRII was generated by mutating the respective wild-type cDNA (Kikutani et al., 1986) and expressed according to example 2 with the mutagenous

- 33 -

primers listed in table 5. For the expression of the protein a pET23a+ vector was chosen.

4.2 Refolding and purification

5 Refolding of shFcεRII was achieved as described in example 1, with the exception that prior to rapid dilution the dissolved inclusion bodies were dialysed against 6M guanidine chloride, 20mM sodium acetate, pH 4.0. shFcεRII was refolded according to example 1 with the respective refolding buffer listed in table 6. After refolding the protein solution was dialysed
10 against PBS, concentrated 100-fold and purified by gel filtration chromatography on Superdex 75. This yielded pure shFcεRII which was dialysed against 2mM TRIS/HCl, 150mM NaCl, 0.02% sodium azide, pH 8.0, concentrated to 10mg/ml and stored at 4°C.

15 Example 5

shFcγRI (soluble human FcγRI)

The procedure was performed according to example 1 except for the indicated changes:

20

5.1 Cloning and Expression

shFcγRI was generated by mutating the respective wild-type cDNA (Allen & Seed, 1988) and expressed according to example 1 with the mutagenous primers listed in table 5. For the expression of the protein a pET32a+
25 vector was chosen, which contains after the N-terminal thioredoxin a hexahistidine-tag with a C-terminal thrombin cleavage site followed by the shFcγRI in frame with the mentioned proteins and amino acid residues. For the overexpression of the fusion protein the E.coli strain BL21(DE3) containing the plasmids pUBS and pLysS (Novagen) was used.

30

The purified inclusion bodies were solubilised in 6M guanidine-HCl, 10mM β-mercaptoethanol, 50mM Tris pH8.0 and bound to a Ni-NTA column

- 34 -

(Qiagen). The elution was performed with an imidazole gradient ranging from 0 to 1M imidazole. The eluted protein was dialysed against a 1000fold volume of 150mM NaCl, 50mM Tris pH8.0, 2mM GSH, 0.5mM GSSG for 24 hours at 4°C. After concentrating the protein solution to 25% of the initial volume, thrombin was added. After 6h of incubation at 37°C the N-terminal thioredoxin and the His-tag were removed completely as verified by N-terminal sequencing. During this digestion the shFcγRI precipitated quantitatively out of solution.

5.2 Refolding and purification

shFcγRI was refolded according to example 1 with the respective refolding buffer listed in table 6. After the redox potential decreased to 1mM the solution was dialysed against PBS pH8.0 and concentrated.

The refolded Protein was analysed by size exclusion chromatography, which yielded a peak of the proposed monomeric receptor and non reducing SDS-PAGE which showed a major band at 30kDa.

Example 6

shFcεRIa (soluble human FcεRIa)

The procedure was performed according to example 1 except for the indicated changes:

6.1 Cloning and Expression

shFcεRI was generated by mutating the respective wild-type cDNA (Kochan et al., 1988) and expressed according to example 1 with the mutagenous primers listed in table 5. For the expression of the protein a pET23a+ vector was chosen.

Brief description of the figures**Fig. 1: 15% reducing SDS PAGE showing the purification of sFcγRIIb**

Lane 1: Molecular weight marker. Lane 2: E. coli lysate before induction.
5 Lane 3: E. coli lysate 1 h after induction. Lane 4: E.coli lysate 4 h after induction. Lane 5: Purified inclusion bodies of sFcγRIIb. Lane 6: Eluate of the hIgG affinity column. Lane 7: Pooled fractions of the gel filtration column.

Fig. 2: Equilibrium gel filtration

10 1 μg hFc solved in 10 μl equilibration buffer (10 μg sFcγRIIb/ml PBS) was applied to a size exclusion chromatography column and the absorbance of the effluent was measured (280 nm) as a function of time. The injected Fc fragment forms a complex with the sFcγRIIb in the equilibration buffer
15 (t = 22min). The negative peak of consumed sFcγRIIb is observed at t = 26 min.

Fig. 3: Overall structure of human sFcγRIIb

20 Stereo ribbon representation of the sFcγRIIb structure. The loops supposed to be important for IgG binding are depicted in red with some of the residues within the binding site and the conserved disulfide bridge in ball and stick representation. The potential N-glycosylation sites are shown as green balls. The termini are labeled and the β-strands are numbered consecutively for the N-terminal domain in black and for the C-terminal
25 domain in blue. The figure was created using the programs MOLSCRIPT (Kraulis, 1991) and RENDER (Merritt and Murphy, 1994).

Fig. 4: Interdomain contacts

30 The figure shows a close-up on the residues involved in the interdomain contacts of sFcγRIIb. The amino acid residues of the N-terminal domain are depicted blue and the residues of the C-terminal domain yellow. The model is covered by a 2Fo-Fc electron density contoured at 1 σ obtained from the

- 36 -

final coordinates. Hydrogen bridges between the domains are represented by white lines. The figure was created using the program MAIN (Turk, 1992).

5 **Fig. 5a: Superposition of the two FcγRIIb domains and the CH2 domain of human IgG1**

Both domains of FcγRIIb and the CH2 domain of hlgG1 were superimposed. The N-terminal domain is depicted in blue, the C-terminal domain in red and the CH2 domain of hlgG1 in green. The respective termini are labeled and
10 the conserved disulfide bridges are depicted as thin lines.

Fig. 5b: Structure based sequence alignment of the sFcγRIIb domains with domains of other members of the FcR family

The upper part of the figure shows the structure based sequence alignment
15 of the FcγRIIb and hlgG1 Fc fragment domains performed with the program GBF-3D-FIT (Lessel & Schomburg, 1994). Amino acid residues with a Cα distance of less than 2.0 Å in the superimposed domains are masked: lilac for matching residues between the Fc fragment domains; yellow for residues in the FcγRIIb domains; and green when they can be superimposed
20 in all four domains. The β-strands are indicated below this part of the alignment and are labeled consistent with Figure 3.

The lower part of the figure shows the alignment of the amino acid sequences from the other FcγRs and the homologue FcεRIa to the profile
25 given in the upper part of the figure using routines from the GCG package (Genetics Computer Group, 1994). The upper and lower row of numbering refer to the N- and C-terminal domains of FcγRIIb. The conserved cysteins are typed in magenta and the potential glycosylation sites in blue. Identical residues within the first domain are masked orange, those in the second domain pink and green when the residues are conserved within both
30 domains. The less conserved third domain of FcγRI is aligned between the first and the second domains. Red arrows point to residues that are involved

in side chain contacts between the first and the second domain while blue arrows depict residues that are relevant for IgG binding. The figure was produced with the program ALSCRIPT (Barton, 1993).

5 **Fig. 6: The putative binding sites of FcγRIIb**

Solid surface representations of FcγRIIb as produced with GRASP (Nicholls et al, 1991), the color coding is according to the relative surface potential from negative (red) to positive (blue). Fig. 6a shows the molecule as in Fig. 3 by a rotation of about 90° counter-clockwise around the vertical. In Fig. 10 6b the molecule is rotated 90° clockwise around the same axis. Both views show the putative binding regions on the C-terminal (Fig. 6a) and the N-terminal domain (Fig. 6b). The amino acid residues discussed in the text are labeled.

15 **Fig. 7: Cα-trace of the superpositioned structures of the Fcγ-receptors**
FcγRIII red, FcγRIIa green and FcγRIIb blue. Residues important for IgG binding are shown in ball-and-stick. The N- and C-termini are labelled.

20 **Fig. 8: Overview of the FcγRIII/Fc-fragment crystal structure in ribbon representation**

The sugar residues bound to the Fc-Fragment are indicated in ball-and-stick. The FcγRIII (blue) binds in the lower hinge region between chain-B (red) and chain-A (green) of the Fc-fragment.

25 **Fig. 9: Close-up on the binding region of the FcγRIII and the Fc-fragment**
The colour scheme is in agreement to figure 8 and residues important for complex formation are shown in ball-and-stick.

Fig. 10a:

30 In the upper part of figure 10a a structure based sequence alignment of the Fc-Receptor ecto-domains is shown. Conserved residues are shaded yellow and identical residues orange. The lower part of the figure shows a part of

the alignment of human antibody sequences. Residues of the human FcγRIII in contact with the Fc-fragment in the complex crystal structure are connected by lines (black for hydrophobic interaction, red for salt bridges and blue for hydrogenbridges). Residues from the Fc-receptor in contact with the A-chain of the Fc-fragment are connected with dashed lines and those in contact with the B-chain of the Fc-fragment with solid lines. Red, blue and black lines represent charged, polar and other contacts, respectively.

Fig. 10b:

In the upper part of figure 10b a structure based sequence alignment of the Fc-Receptor ecto-domains is shown. Conserved residues are shaded yellow and identical residues orange. Conserved residues within the less related Kir and FcA-Receptor sequences are shaded blue. The lower part of the figure shows a part of the alignment of human antibodies with the mouse IgE (mIgE) sequence. Residues of the human FcγRIII in contact with the Fc-fragment in the complex crystal structure are connected by lines (black for hydrophobic interaction, red for salt bridges and blue for hydrogenbonds). Residues from the Fc-receptor in contact with the A-chain of the Fc-fragment are connected with dashed lines and those in contact with the B-chain of the Fc-fragment with solid lines. Red, blue and black lines represent charged, polar and other contacts, respectively.

Fig. 11 and Fig. 12:

Fig. 11 and Fig. 12 show an alignment of the produced sFcγR, sFcεRIa and the short form of sFcεRII and the produced sFcγR and sFcεRIa without sFcεRII, respectively.

Table 1: Crystallographic results

The obtained preliminary crystallographic data are shown in this table.

	Orthorhombic	Tetragonal	Hexagonal
Space group	P2 ₁ 2 ₁ 2 ₁ [19]	P4 ₂ 2 ₁ 2 [94]	P3 [143]
Unit cell dimensions	a = 40.8 Å, b = 50.9 Å, c = 80.5 Å, α = 90°, β = 90°, γ = 90°	a = 85.7 Å, b = 85.7 Å, c = 63.4 Å, α = 90°, β = 90°, γ = 90°	a = 80.9 Å, b = 80.9 Å, c = 157.0 Å, α = 90°, β = 90°, γ = 90°
R _{merge}	5.8%	9.8%	13.6%
Resolution	1.7 Å	2.7 Å	3.8 Å
Unique	18,040	6,616	7,210
Completeness	89.1%	97.1%	63.0%
Multiplicity	3.5	4.4	1.3
V _M , molecules per asymmetric unit, solvent content	2.09 Å ³ /Da, 1 mol., 41% solvent	2.91 Å ³ /Da, 1 mol, 58% solvent	2.97 Å ³ /Da, 5 mol, 59% solvent

Table 2: Data collection statistics

Derivative	Space Group	No. of unique reflections	Multiplicity	Resolution (Å)	Completeness (overall/last shell) (%/%)	R _m (%)	No. of sites	Phasing power
NATl	P2 ₁ 2 ₁ 2 ₁	18009	3.6	1.74	92.9/86.4	5.5		
NATl	P4 ₂ 2 ₁ 2	6615	4.5	2.70	97.1/94.3	10.1		
NATl-Baculo	P3 ₂ 21	3545	2.5	3.0	93.0/98.9	14.4		
UOAc	P2 ₁ 2 ₁ 2 ₁	7722	4.2	2.1	96.8/95.7	7.3	1	1.79
PtPy	P2 ₁ 2 ₁ 2 ₁	5520	3.9	2.3	89.7/49.6	10.5	1	1.39

$$R_m = \sum |I_h - \langle I_h \rangle| / \sum \langle I_h \rangle$$

Phasing power: $\langle F_H \rangle / E$, where $\langle F_H \rangle = \sum (F_H^2 / n)^{1/2}$ is the r.m.s. heavy atom structure amplitude.

$E = \sum [(F_{PHC} - F_{PH})^2 / n]^{1/2}$ is the residual lack of closure error with F_{PH} being the structure factor amplitude and $F_{PHC} = |F_P + F_H|$ the calculated structure factor amplitude of the derivative.

Table 3: Refinement statistics

	Resolution range (Å)	8.0 - 1.74 Å
	No. of unique reflections ($F > 0\sigma(F)$)	16252
5	R factor R_{free}	19.4 27.9
	No. of atoms per asymmetric unit protein solvent	1371 150
10	Rms deviation from ideal geometry bond length (Å) bond angle (°)	0.009 2.007
15	Average B factors (Å ²) protein main chain protein side chain solvent	18.8 25.2 36.7
	Rms deviation of bonded B factors (Å ²)	4.1

20 R_{free} : 5% of the reflections were used as a reference data set and were not included in the refinement.

Table 4: Residues that contribute to the interdomain contact via side chains

25	FcγRIIb	FcγRIIa	FcγRIII	FcγRI	FcεRIa
	Asn15	Asn	Ser	Ser	Arg
	Asp20	Asp	Asp	Glu	Glu
	Gln91	Gln	Gln	Gln	Gln
	His108	His	His	His	His
30	Trp110	Trp	Trp	Trp	Trp

Table 5: Primers used for the amplification of the FcRs

Construct	5'-Primer	3'-Primer
sFcγRI	5'-CACCCATATGGCAGTGATCTCTTT-3'	5'- AGGACTCGAGACTAGACAGGAGTTGGTA AC-3'

- 41 -

sFcγRIIa	5'-ACAGT <u>CATATGG</u> CAGCTCCCC-3'	5'- AAAAAAGCTTCAGGGCACTTGGAC-3'
sFcγRIIb	5'- AATT <u>CCATGGG</u> GACACCTGCAGCTCCC-3'	5'- CCCAGTGT <u>CGACAGCCT</u> AAATGATCCCC-3'
sFcγRIII	5'-AAAAAA <u>CATATG</u> CGGACTGAAG-3'	5'-AAAAAAGCTTAACCTTGAGTGATG-3'
sFcεRIa	5'-GATGGCCATATGGCAGTCCCTCAG-3'	5'- CAATGGAT <u>CCT</u> AAAATTGTAGCCAG-3'
sFcεRII	5'-AAAAAA <u>CATATG</u> GAGTTGCAGG-3'	5'-TGGCTGGATCCATGCTCAAG-3'

Introduced restriction sites are underlined, start- and stop-codons are depicted as bold-italics

10 Table 6: Refolding Conditions for the FcRs

Construct	Buffer
sFcγRI	0.1M TRIS/HCl, 1.2M arginine, 150mM NaCl, 5mM GSH, 0.5mM GSSG, 0.02% sodium azide, pH 8.0
sFcγRIIa	0.1M TRIS/HCl, 1.4M arginine, 150mM NaCl, 2mM GSH, 0.5mM GSSG, 0.02% sodium azide, pH 8.0
sFcγRIIb	0.1M TRIS/HCl, 1.4M arginine, 150mM NaCl, 5mM GSH, 0.5mM GSSG, 0.02% sodium azide, pH 8.0
15 sFcγRIII	0.1M TRIS/HCl, 1.0M arginine, 150mM NaCl, 2mM GSH, 0.5mM GSSG, 0.02% sodium azide, pH 8.0
sFcεRII	0.1M TRIS/HCl, 0.8M arginine, 150mM NaCl, 5mM GSH, 0.5mM GSSG, 0.02% sodium azide, pH 8.3

Table 7: Crystallisation Conditions for the FcRs

Construct	Condition	Space group, cell constants	Resolution
20 sFcγRIIa	26% PEG 8000, 0.2M sodium acetate/acetic acid pH 4.6, 0.02% sodium azide	C2, a=80.4Å, b=49.7Å, c=54.6Å, a=g=90°, b=128.1°	3.0Å

- 42 -

sFcγRIIb	33% PEG 2000, 0.2M sodium acetate, 0.02% sodium azide, pH 5.4	P212121, a=40.8Å, b=50.9Å, c=80.5Å, a=b=g=90°	1.7Å
sFcγRIII	22% PEG 8000, 0.1M MES/TRIS pH 7.8, 0.02% sodium azide	P22121, a=36.7Å, b=60.3Å, c=85.6Å, a=b=g=90°	2.5Å
sFcγRIII: hFc1	6% PEG 8000, 0.1M MES/TRIS pH 5.6, 0.2M Na/K tartrate, 0.02% sodium azide	P6522, a=b=115.0Å, c=303.3Å, a=b=90°, g=120°	3.3Å
sFcγRIII	22% PEG 8000, 0.1M MES/TRIS pH 7.8, 0.02% sodium azide	P22121, a=36.7Å, b=60.3Å, c=85.6Å, a=b=g=90°	2.5Å

References

- Ades, E.W., Phillips, D.J., Shore, S.L., Gordon, D.S., LaVia, M.F., Black, C.M., Reimer, C.B. (1976), Analysis of mononuclear cell surfaces with fluoresceinated Staphylococcal protein A complexed with IgG antibody or heat-aggregated γ -globulin, J. Immunol. 117, 2119.
- Allen J.M., Seed B.; "Nucleotide sequence of three cDNAs for the human high affinity Fc receptor (FcRI)"; Nucleic Acids Res. 16:11824-11824(1988).
- Amigorena, S., Bonnerot, C., Drake, J.R., Choquet, D., Hunziker, W., Guillet, J.G., Webster, P., Sautes, C., Mellman, I., Fridman, W.H. (1992), Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes, Science 256, 1808-1812.
- Barton, G.C. (1993), ALSCRIPT: tool to format multiple sequence alignments, Prot. Eng. 6, 37-40.
- Bazil, V. and Strominger, J.L. (1994), Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes, J. Immunol. 152, 1314-1322.
- Brünger, A.T., Kuriyan, J., Karplus, M. (1987), Crystallographic R factor refinement by molecular dynamics, Science 35, 458-460.
- Burmeister, W.P., Huber, A.H., Bjorkman, P.J. (1994), Crystal structure of the complex of rat neonatal Fc receptor with Fc, Nature 372, 379-383.
- Ceuppens, J.L., Baroja, M.L., van Vaeck, F., Anderson, C.L. (1988), Defect in the membrane expression of high affinity 72kD Fc γ receptors on phagocytic cells in four healthy subjects, J. Clin. Invest. 82, 571-578.

Collaborative computational project, Number 4 (1994), The CCP4 suite: Programs for protein crystallography, *Acta crystallogr.* D50, 760-763.

Deisenhofer, J., Jones, T.A., Huber, R., Sjodahl, J., Sjoquist, J. (1978),
5 Crystallization, crystal structure analysis and atomic model of the complex
formed by a human Fc fragment and fragment B of protein A from
Staphylococcus aureus, *Z. Phys. Chem.* 359, 975-985.

Deisenhofer, J. (1981), Crystallographic refinement and atomic models of
10 a human Fc fragment and its complex with fragment B of protein A from
Staphylococcus aureus at 2.9- and 2.8Å resolution, *Biochemistry* 20,
2361-2370.

Deisenhofer J., Colman PM., Huber R., Haupt H., Schwick G.;
15 "Crystallographic structural studies of a human Fc-fragment. I. An electron-
density map at 4Å resolution and a partial model"; *Hoppe-Seyler's Z.*
Physiol. Chem. 357:435-445(1976).

Dulau, L., Cheyrou, A., Aigle, M. (1989), Directed mutagenesis using PCR,
20 *Nucleic Acids Res.* 17, 2873.

Ellman (1959), Tissue sulfhydryl groups, *Arch. Biochem. Biophys.* 82, 79-
77.

25 Engelhardt, W., Geerds, C., Frey, J. (1990), Distribution, inducibility and
biological function of the cloned and expressed human β Fc receptor II, *Eur.*
J. Immunol. 20, 1367-1377.

Engh, R.A. and Huber, R. (1991), Accurate bond and angle parameters for
30 X-ray protein structure refinement, *Acta crystallogr.* A47, 392-400.

Fleit, H.B., Kobasiuk, C.D., Daly, C., Furie, R., Levy, P.C., Webster, R.O. (1992), A soluble form of FcγRIII is present in human serum and other body fluids and is elevated at sites of inflammation, *Blood* 79, 2721-2728.

5 Fridman, W.H., Bonnerot, C., Daeron, M., Amigorena, S., Teillaud, J.-L., Sautès, C. (1992), Structural bases of Fcγ receptor functions, *Immunol. Rev.* 125, 49-76.

10 Fridman, W.H., Teillaud, J.-L., Bouchard, C., Teillaud, C., Astier, A., Tartour, E., Galon, J., Mathiot, C., Sautès, C. (1993), Soluble Fcγ receptors, *J. Leukocyte Biol.* 54, 504-512.

15 Gabb, H.A., Jackson, R.M., Sternberg, M.J.E. (1997), Modelling protein docking using shape complementarity, electrostatics and biochemical information, *J. Mol. Biol.* 272, 106-120.

Galon, J., Bouchard, C., Fridman, W.H., Sautès, C. (1995), Ligands and biological activities of soluble Fcγ receptors, *Immunol. Lett.* 44, 175-181.

20 Genetics Compouter Group (1994), Program Manual for the Wisconsin Package Version 8, Madison, Wisconsin.

Gordon, J. et al., (1980), The molecules controlling B lymphocytes. *Immunol. Today*, 8: 339-344.

25 Grodberg, J. and Dunn, J.J. (1988), OmpT encodes the Escherichia coli outer membrane protease that cleaves T7 RNA polymerase during purification, *J. Bacteriol.* 170, 1245-1253.

30 Hogarth, P.M., Hulett, M.D., Ierino, F.L., Tate, B., Powell, M.S., Brinkworth, R.I. (1992), Identification of the immunoglobulin binding regions (IBR) of FcγRII and FcεRI, *Immunol. Rev.* 125, 21-35.

- 46 -

Homsy, J., Meyer, M., Tateno, M., Clarkson, S., Levy, J.A. (1989), The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells, *Science* 244, 1357-1360.

- 5 Hoover, R.G., Lary, C., Page, R., Travis, P., Owens, R., Flick, J., Kornbluth, J., Barlogie, B. (1995), Autoregulatory circuits in myeloma: Tumor cell cytotoxicity mediated by soluble CD16, *J. Clin. Invest.* 95, 241-247.

- 10 Huber, R., Deisenhofer, J., Colman, P.M., Matsushima, M. and Palm, W. (1976), Crystallographic structure studies of an IgG molecule and an Fc fragment, *Nature* 264, 415-420.

- 15 Hulett, M.D., Witort, E., Brinkworth, R.I., McKenzie, I.F.C., Hogarth, P.M. (1994), Identification of the IgG binding site of the human low affinity receptor for IgG FcγRII, *J. Biol. Chem.* 269, 15287-15293.

- Hulett, M.D., Witort, E., Brinkworth, R.I., McKenzie, I.F.C., Hogarth, P.M. (1995), Multiple regions of human FcγRII (CD32) contribute to the binding of IgG, *J. Biol. Chem.* 270, 21188-21194.

- 20 lerino, F.L., Powell, M.S., McKenzie, I.F.C., Hogarth, P.M. (1993), Recombinant soluble human FcγRII: Production, characterization, and inhibition of the arthus reaction, *J.Exp. Med.* 178, 1617-1628.

- 25 Jancarik, J. and Kim, S.H. (1991), Sparse matrix sampling: A screening method for crystallization of proteins, *J. Appl. Crystallogr.* 24, 409-411.

- 30 Jones, T.A., Zou, J.-Y., Cowan, S.W., Kjeldgaard, M. (1991), Improved methods for building protein models in electron density maps and the location of errors in these models, *Acta crystallogr.* A47, 110-119.

- 47 -

Kikutani H., Inui S., Sato R., Barsumian E.L., Owaki H., Yamasaki K., Kaisho T., Uchibayashi N., Hardy R.R., Hirano T., Tsunasawa S., Sakiyama F., Suemura M., Kishimoto T.; "Molecular structure of human lymphocyte receptor for immunoglobulin E"; *Cell* 47(5):657-665(1986).

5

Khayat, D., Soubrane, C., Andriew, J.M., Visonneau, S., Eme, D., Tourani, J.M., Beldjord, K., Weil, M., Fernandez, E., Jaquillat, C. (1990), Changes of soluble CD16 levels in serum of HIV patients: Correlation with clinical and biological prognostic factors, *J. Infect. Dis.* 161, 430-435.

10

Kochan J., Pettine L.F., Hakimi J., Kishi K., Kinet J.P.; "Isolation of the gene coding for the alpha subunit of the human high affinity IgE receptor"; *Nucleic Acids Res.* 16:3584-3584(1988).

15

Simmons D., Seed B.; "The Fc-gamma receptor of natural killer cells is a phospholipid-linked membrane protein"; *Nature* 333:568-570(1988).

Kraulis, P.J. (1991), MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures, *J. Appl. Cryst.* 24, 946-950.

20

Leslie, A.G.W. (1997), Mosflm user guide, mosflm version 5.50, MRC Laboratory of Molecular Biology, Cambridge, UK.

Lessel, U. and Schomburg, D. (1994), Similarities between protein 3-D structures, *Protein Eng.* 7, 1175-1187.

25

Littaua, R., Kurane, I. and Ennis, F.A. (1990), Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection, *J. Immunol.* 144, 3183-3186.

30

Lynch, R.G., Hagen, M., Mueller, A., Sandor, M. (1995), Potential role of FcγR in early development of murine lymphoid cells: Evidence for functional

interaction between FcγR on pre-thymocytes and an alternative, non-Ig ligand on thymic stromal cells, *Immunol. Lett.* 44, 105-109.

Mathiot, C., Teillaud, J.L., Elmalek, M., Mosseri, L., Euller-Ziegler, L.,
5 Daragon, A., Grosbois, B., Michaux, J.L., Facon, T., Bernard, J.F., Duclos, B., Monconduit, M., Fridman, W.H. (1993), Correlation between serum soluble CD16 (sCD16) levels and disease stage in patients with multiple myeloma, *J. Clin. Immunol.* 13, 41-48.

10 Merritt, E.A. and Murphy, M.E.P. (1994), Raster3D Version 2.0. A program for photorealistic molecular graphics, *Acta Cryst.* D50, 869-873.

Metzger, H. (1992A), Transmembrane signaling: The joy of aggregation, *J. Immunol.* 149, 1477-1487.

15 Metzger, H. (1992B), The receptor with high affinity for Ig E, *Immunol. Rev.* 125, 37-48.

Müller, S. and Hoover, R.G. (1985), T cells with Fc receptors in myeloma;
20 suppression of growth and secretion of MOPC-315 by T alpha cells, *J. Immunol.* 134, 644-7.

Nicholls, A., Sharp, K.A., Honig, B. (1991), Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons,
25 *Proteins* 11, 281-296.

Poo, H., Kraus, J.C., Mayo-Bond, L., Todd, R.F., Petty, H.R. (1995), Interaction of Fcγ receptor IIIB with complement receptor type 3 in fibroblast transfectants: evidence from lateral diffusion and resonance
30 energy transfer studies, *J. Mol. Biol.* 247, 597-603.

Rappaport, E.F., Cassel, D.L., Walterhouse, D.O., McKenzie, S.E., Surrey, S., Keller, M.A., Schreiber, A.D., Schwartz, E. (1993), A soluble form of the human Fc receptor FcγRIIa: cloning, transcript analysis and detection. *Exp. Hematol.* 21, 689-696.

5

Ravanel, K., Castelle, C., Defrance, T., Wild, T.F., Charron, D., Lotteau, V., Rabourdincombe, C. (1997), Measles virus nucleocapsid protein binds to FcγRII and inhibits human B cell antibody production. *J. Exp. Med.* 186, 269-278.

10

Roman, S., Moore, J.S., Darby, C., Muller, S., Hoover, R.G. (1988), Modulation of Ig gene expression by Ig binding factors. Suppression of alpha-H chain and lambda-2-L chain mRNA accumulation in MOPC-315 by IgA-binding factor, *J. Immunology* 140, 3622-30.

15

Sarfat, D. et al., (1988), Elevation of IgE-binding factors of serum in patients with B-cell derived chronic lymphocytic leukemia. *Blood*, 71: 94-98.

20

Sauer-Eriksson, A.E., Kleywegt, G.J., Uhlen, M., Jones, T.A. (1995), Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG, *Structure* 3, 265-78.

25

Small, T., et al., (1990), B-cell differentiation following autologous, conventional or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. *Blood*, 76: 1647-1656.

30

Sondermann, P., Huber, R., Jacob, U. (1998B), Preparation and crystallization of active soluble human FcγRIIb derived from E.coli, *Protein Structure*, submitted.

- 50 -

Sondermann, P., Kutscher, C., Jacob, U., Frey, J. (1998A),
Characterization and crystallization of soluble human Fc γ recep
tor 11 isoforms produced in insect cells, Biochemistry, submitted.

5 Sondermann, P., Kutscher, C., Jacob, U., Frey, J., Analysis of complexes
of IgG and soluble human Fc γ -Receptor II produced in insect cells and its
crystallization, submitted.

Stengelin S., Stamenkovic I., Seed B.; "Isolation of cDNAs for two distinct
10 human Fc receptors by ligand affinity cloning"; EMBO J. 7:1053-
1059(1988).

Tax, W.J.M., Willems, H.W., Reekers, P.P.M., Capel, P.J.A., Koene, R.A.P.
(1983), Polymorphism in mitogenic effect of IgG1 monoclonal antibodies
15 against T3 antigen on human T cells, Nature 304, 445-447.

Teillaud, J.L., Brunati, S., Elmalek, M., Astier, A., Nicaise, P., Moncuit, J.,
Mathiot, C., Job-Deslandre, C., Fridman, W.H. (1990), Involvement of
FcR+ T cells and of IgG-BF in the control of myeloma cells, Mol. Immunol.
20 27, 1209-17.

Turk, D. (1992), Ph.D. Thesis, TU München, Germany.

Ulvestad, E., Matre, R., Tonder, O. (1988), IgG Fc receptors in sera from
25 patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus,
Scand. J. Rheumatol., Suppl. 75, 203-208.

van de Winkel, J.G.J. and Capel, P.J.A. (1993), Human IgG Fc receptor
heterogeneity: Molecular aspects and clinical implications, Immunol. Today
30 14, 215-221.

Varin, N., Sautès, C., Galinha, A., Even, J., Hogarth, P.M., Fridman, W.H. (1989), Recombinant soluble receptors for the Fc γ portion inhibit antibody production in vitro, Eur. J. Immunol. 19, 2263-2268.

- 5 Yang, Z., Delgado, R., Xu, L., Todd, R.F., Nabel, E.G., Sanchez, A., Nabel, G.J. (1998), Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins, Science 279, 983-984.

- 10 Zhou, M.-J., Todd, R.F., van de Winkel, J.G.J., Petty, H.R. (1993), Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fc γ receptor III on human neutrophils. Possible role of lectin-like interactions, J. Immunol. 150, 3030-3041.

Claims

1. Recombinant soluble Fc receptor
characterized by the absence of transmembrane domains, signal
peptide and glycosylation.
5
2. Recombinant Fc receptor according to claim 1,
wherein the receptor is a FcγR or a FcεR.
- 10 3. Recombinant Fc receptor according to claim 1 or 2,
wherein the receptor is a FcγRIIb.
4. Recombinant Fc receptor according to any one of claims 1 to 3,
wherein the receptor is of human origin.
15
5. Recombinant Fc receptor according to any one of claims 1 to 4,
wherein it contains one of the amino acids as shown in one of SEQ
ID NOs:1-6.
- 20 6. Recombinant nucleic acid containing a sequence encoding a
recombinant Fc receptor according to any one of claims 1 to 5.
7. Recombinant nucleic acid according to claim 6,
wherein it contains one of the sequences as shown in one of SEQ ID
25 NOs:7-12.
8. Recombinant nucleic acid according to claim 6 or 7,
wherein it additionally contains expression control sequences
operably linked to the sequence encoding the recombinant Fc
30 receptor.
9. Recombinant nucleic acid according to any one of claims 6 to 8,

wherein it is contained on a prokaryotic expression vector, preferably a pET vector.

- 5 10. Host cell characterized by the presence of a recombinant nucleic acid according to any one of claims 6 to 8.
11. Host cell according to claim 10,
wherein it is a prokaryotic host cell, preferably an E. coli cell.
- 10 12. Process for the determination of the amount of antibodies of a certain type in the blood, plasma or serum of a patient, characterized by the use of a recombinant soluble Fc receptor according to any one of claims 1 to 5 in an immunoassay and determination of the presence of FcR-antibody complexes.
- 15 13. Process according to claim 12, wherein the immunoassay is an ELISA and preferably a sandwich assay.
- 20 14. Process according to claim 12 or 13, wherein the antibodies to be determined are IgE antibodies and the recombinant soluble receptor is a FcεR.
- 25 15. Process according to claim 14 for the determination of a predisposition or manifestation of an allergy.
- 30 16. Process according to claim 12 or 13, wherein the antibodies to be determined are IgG antibodies and the recombinant soluble receptor is a FcγR.
17. Process for the determination of the immune status of patients with chronic diseases of the immune system, wherein a Fc receptor according to any one of claims 1 to 5 is used in a competitive

immunoassay and the amount of the corresponding sFcRs in the blood, plasma or serum of a patient is determined.

- 5 18. Process according to claim 17, wherein the chronic disease is AIDS, SLE, MM or rheumatoid arthritis.
19. Use of a recombinant soluble Fc receptor according to any one of claims 1 to 5 for the screening of substances in view of their ability to act as inhibitors of the recognition and binding of antibodies to the
10 respective cellular receptors.
20. Use according to claim 19, wherein recombinant soluble FcγRs are used and recognition and binding of IgG antibodies is of interest.
- 15 21. Pharmaceutical composition containing as active agent a recombinant soluble FcR according to any one of claims 1 to 5.
22. Pharmaceutical composition according to claim 21 for use in the treatment or prevention of autoimmune diseases, allergies or tumor
20 diseases.
23. Pharmaceutical composition according to claim 21 or 22 for use in the treatment of AIDS, rheumatoid arthritis or multiple myeloma, containing a recombinant soluble FcγR preferably having the amino
25 acid sequence as shown in SEQ ID NO:1.
24. Crystalline preparation of a soluble recombinant Fc receptor according to claims 1 to 5.
- 30 25. Crystalline preparation of a soluble recombinant Fc receptor / immunoglobulin complex.

26. Use of a crystalline preparation of a recombinant soluble Fc receptor according to any one of claims 1 to 5 for the generation of crystal structure data of Fc receptors.
- 5 27. Use of a crystalline preparation of a soluble recombinant Fc receptor / immunoglobulin complex for the generation of crystal structure data of receptor / Ig complexes and their respective binding sites.
- 10 28. Use of crystal structure data obtained by the use according to claims 26 or 27 for the identification and/or preparation of Fc receptor or immunoglobulin inhibitors.
- 15 29. Use of crystal structure data obtained by the use according to claim 26 or 27 for the identification and preparation of new antibody receptors.
30. Use according to any one of claims 26 to 29 in a computer-aided modelling program.
- 20 31. FcR inhibitor characterized in that it has a three-dimensional structure which is complementary to the recombinant soluble FcR according to any one of claims 1 to 5.
- 25 32. Immunoglobulin-inhibitor, characterized in that it has a three-dimensional structure which is complementary to an Fc receptor binding site of an immunoglobulin.
- 30 33. Pharmaceutical composition containing as active agent a FcR inhibitor according to claim 31.
34. Pharmaceutical composition containing as active agent an immunoglobulin inhibitor according to claim 32.

35. Pharmaceutical composition according to claim 33 or 34 for use in the treatment or prevention of diseases which are due to overreactions or faulty reactions of the immune system.
- 5 36. Pharmaceutical composition according to claim 33, 34 or 35 for the treatment or prevention of allergies, autoimmune diseases or an anaphylactic shock.
- 10 37. Use of a molecule for the modulation of the interaction between Fc receptor and immunoglobulin, characterized in that the molecule is designed or identified using crystal structure data obtained from crystalline preparations according to claims 24 or 25.
- 15 38. Use according to claim 37, wherein the modulation is partial or complete inhibition of binding between Fc receptor and immunoglobulin.
39. Fc receptor according to claims 1-5, bound to a solid phase.
- 20 40. Fc receptor according to claim 39, wherein the solid phase is a chromatography carrier material.
- 25 41. Use of a chromatography carrier material according to claim 40 for the adsorption of immunoglobulins from the blood, plasma or serum of a patient or from culture supernatants of immunoglobulin producing cells.
- 30 42. Use according to claim 41 for the enrichment of antibodies from a patient's blood, serum or plasma or from culture supernatants of immunoglobulin producing cells for the conduction of further tests.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5A



FIG. 5B




FIG. 6




FIG. 7




FIG. 8




FIG. 9

10/14




FIG. 10a




FIG. 10b

Alignment of the produced sFcγR, sFcεR1a and the short form of sFcεR1I

sFcγRIIa	---MAAPPKAVLKLEPP-WINV LQEDSVTLTCQGARSPESDSIQWFHN-GNLIPHTHTQPS	55
sFcγRIIb	MGT PAAPPKAVLKLEPQ-WINV LQEDSVTLTCRGTHSPESDSIQWFHN-GNLIPHTHTQPS	58
sFcγRIII	-MRTEDLPKAVVFLEPQ-WYSVLEKDSVTLKCQGAYSPEDNSTQWFHN-ESLISSQASSY	57
sFcγRI	-----MAVISLQPP-WVSVFQEETVTLHCEVLHLP GSSSTQWFLN-GTATQTSTPSY	50
sFcεR1a	---MAVPQKPKVSLNPP-WNRIFKGENVTLT CNGNNFFEVSSTKW FHN-GSLSEETNSSL	55
sFcεRII	-MELQVSSGFVCNTCPEKWINFQRK-----C---YYFGKGTKQWVHARYACDDMEGQLV	50
	* * . . * . : : *	
sFcγRIIa	YRFKANNND SG-EYTCQTGQTSLSDPVHLTVLSEWLV-LQTPHLEFQEGETIMLRCHSWK	113
sFcγRIIb	YRFKANNND SG-EYTCQTGQTSLSDPVHLTVLSEWLV-LQTPHLEFQEGETIVLRCHSWK	116
sFcγRIII	FIDAATVND SG-EYRCQTNLSTLSDPVQLEVHIGWLL-LQAPRWVFKEEDPIHLRCHSWK	115
sFcγRI	RITSASVND SG-EYRCQRGLSGRSDPIQLEIHRGWLL-LQVSSRVFTEGEPLALRCHAWK	108
sFcεR1a	NIVNAKFED SG-EYKCQHQQVNESEPVYLEVFSDWLL-LQASAEVVMEGQPLFLRCHGWR	113
sFcεRII	SIHSPEEQDFLT KHASHTGSGWIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTS-RSQGED	109
	. : * : : : : * * : : . : * . .	
sFcγRIIa	DKPLVKVTF FQNGK-SQKFSRLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTTITVQ	172
sFcγRIIb	DKPLVKVTF FQNGK-SKKFSRSDPNFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTTITVQ	175
sFcγRIII	NTALHKVTYLQNGK-DRKYFHNSDFHIPKATLKDSGSYFCRGLVGSKNVSETVNITIT	174
sFcγRI	DKLVYNVLYYRNGK-AFKFFHWSNLTI LKTNISHNGTYHCSG-MGKHRYTSAGISVTVK	166
sFcεR1a	NWDVYKVIYYKDGE-ALKYWYENHNISITNATVEDSGTYICTGKVVWQLDYESEPLNITVI	172
sFcεRII	CVMMRGSGRWND AFCDRKLGAWVCDRLATCTPPASEGSAESMGPD SRPDGRLPTPSAP	169
	: . . * : . * . * . . :	
sFcγRIIa	VP-----	174
sFcγRIIb	APSSSPMGII-----	185
sFcγRIII	QG-----	176
sFcγRI	ELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQ	226
sFcεR1a	KAPREKYWLQF-----	183
sFcεRII	LHS-----	172
sFcγRIIa	-----	
sFcγRIIb	-----	
sFcγRIII	-----	
sFcγRI	ILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPV	269
sFcεR1a	-----	
sFcεRII	-----	

FIG. 11

Alignment the produced sFcγR and sFcεRIa without sFcεRII

```

sFcγRIIa      ---MAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYR 57
sFcγRIIb      MGTPAAPPKAVLKLEPQWINVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYR 60
sFcγRIII      -MRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQWFHNESLISSQASSYFI 59
sFcγRI        -----MAVISLQPPWVSFQEETVTLHCEVLLHLPGSSSTQWFNLGTATQTSTPSYRI 52
sFcεRIa       ---MAVPQKPKVSLNPPWNRIFKGENVTLTGNNFFEVSSTKWFHNGSLSEETNSSLNI 57
               . : * : * * : : : . : * * * * . . * : * * * .

sFcγRIIa      FKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLTQPHLEFQEGETIMLRCHSWKDKPL 117
sFcγRIIb      FKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLTQPHLEFQEGETIVLRCHSWKDKPL 120
sFcγRIII      DAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLQAPRWVFKEEDPIHLRCHSWKNTAL 119
sFcγRI        TSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLQVSSRVFTEGEPLALRCHAWKDKLV 112
sFcεRIa       VNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLWLLQASAEVVMGQPLFLRCHGWRNWDV 117
               * . : * * * * * * * : * : * : * : * * . . * : : : * * * . * : : :

sFcγRIIa      VKVTFQNGKSKQFSRLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVITITVQVP--- 174
sFcγRIIb      VKVTFQNGKSKKFSRSDPNFSIPQANHSHSGDYHCTGNIGYTLYSSKPVITITVQAPSSS 180
sFcγRIII      HKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKNVSSSETVNITITQG--- 176
sFcγRI        YNVLYYRNGKAFKFFHWNNSNLITLKTNI SHNGTYHCSG-MGKHRYTSAGISVTVKELFPA 171
sFcεRIa       YKVIYYKDGEALKYWYENHNISITNATVEDSGTYCTGKVVQLDYESEPLNITVIKAPRE 177
               : * : : * : * : : : * : : . . . * * * * : * : : * :

sFcγRIIa      -----
sFcγRIIb      PMGII----- 185
sFcγRIII      -----
sFcγRI        PVLNASVTSPLLEGNLVTLSCETKLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTAR 231
sFcεRIa       KYWLQF----- 183

sFcγRIIa      -----
sFcγRIIb      -----
sFcγRIII      -----
sFcγRI        REDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPV 269
sFcεRIa       -----

```

FIG. 12

Prot in sequences of the examples (mutated to yield soluble forms)

>sFcγRI

SEQ ID NO: 1

MAVISLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYRITSASVND
GEYRCQRGLSGRSDPIQLEIHRGWLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYYRN
GKAFKFFHWNSNLTKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTS
PLLEGNLVTLSKETKLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTARREDSGLYWC
EAATEDGNVLKRSPELELQVLGLQLPTPV

>sFcγRIIa

SEQ ID NO: 2

MAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKA
NNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKV
TFFQNGKSQKFSRLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVP

>sFcγRIIb

SEQ ID NO: 3

AGTPAAPPKAVLKLEPPQWINVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYR
FKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPL
VKVTFFQNGKSKKFSRSDPNFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSS
PMGII

>sFcγRIII

SEQ ID NO: 4

MRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQWFHNESLISSQASSYFID
AATVNDSEYRCQTNLSTLSDPVQLEVHIGWLLQAPRWVFKEEDPIHLRCHSWKNTALH
KVTYLQNGKDRKYFHHNSDFHIPKATLKDGSYFCRGLVGSKNVSSSETVNITITQG

>sFcεRIa

SEQ ID NO: 5

MAVPQKPKVSLNPPWNRIFKGENVTLTGNGNFFEVSSTKWFHNGSLSEETNSSLNIVN
AKFEDSGEYKQHQVNESEPVYLEVFSDWLLQASAEVVMEGQPLFLRCHGWRNWDVYK
VIYYKDGEALKYWYENHNISITNATVEDSGTYCTGKVVQLDYESEPLNITVIKAPREKY
WQLQF

>sFcεRII

SEQ ID NO: 6

MDTTQSLKQLEERAARNVSQVSKNLESHHGDQMTQKSQSTQISQELEELRAEQQRLKSQD
LELSWNLNGLQADLSSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEK
WINFQRKCYFYGKGTKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNL
DLKGEFIWVDGSHVDYSNWAPEPTSRSQGEDCVMRGRSGRWNDAFCDRKLGAWVCDRLA
TCTPPASEGSAESMGPDSPDPDGRLPDTPSAPLHS

DNA sequences of the examples (mutated to yi Id soluble forms)

SEQ ID NO: 7

>sFyRI

1	CATATGGCAG	TGATCTCTTT	GCAGCCTCCA	TGGGTCAGCG	TGTTCCAAGA	GGAAACCGTA	60
61	ACCTTGCAC	GTGAGGTGCT	CCATCTGCCT	GGGAGCAGCT	CTACACAGTG	GTTTCTCAAT	120
121	GGCACAGCCA	CTCAGACCTC	GACCCCCAGC	TACAGAATCA	CCTCTGCCAG	TGTCAATGAC	180
181	AGTGGTGAAT	ACAGGTGCCA	GAGAGGTCTC	TCAGGGCGAA	GTGACCCCAT	ACAGCTGGAA	240
241	ATCCACAGAG	GCTGGCTACT	ACTGCAGGTC	TCCAGCAGAG	TCTTCACGGA	AGGAGAACCT	300
301	CTGGCCTTGA	GGTGTCTATG	GTGGAAGGAT	AAGCTGGTGT	ACAATGTGCT	TTACTATCGA	360
361	AATGGCAAAG	CCTTTAAGTT	TTTCCACTGG	AATTCTAACC	TCACCATTCT	GAAAACCAAC	420
421	ATAAGTCACA	ATGGCACCTA	CCATTGCTCA	GGCATGGGAA	AGCATCGCTA	CACATCAGCA	480
481	GGAATATCTG	TCACTGTGAA	AGAGCTATTT	CCAGCTCCAG	TGCTGAATGC	ATCTGTGACA	540
541	TCCCCACTCC	TGGAGGGGAA	TCTGGTCACC	CTGAGCTGTG	AAACAAAGTT	GCTCTTGCAG	600
601	AGGCCTGGTT	TGCAGCTTTA	CTTCTCCTTC	TACATGGGCA	GCAAGACCCT	GCGAGGCAGG	660
661	AACACATCCT	CTGAATACCA	AATACTAACT	CTAGAAGAG	AAGACTCTGG	GTTATACTGG	720
721	TGCGAGGCTG	CCACAGAGGA	TGGAATGTGC	CTTAAGCGCA	GCCCTGAGTT	GGAGCTTCAA	780
781	GTGCTTGGCC	TCCAGTTACC	AACTCCTGTC	TAGTCTCGAG			820

SEQ ID NO: 8

>sFcyRIIa

1	CATATGGCAG	CTCCCCAAA	GGCTGTGCTG	AAACTTGAGC	CCCCGTGGAT	CAACGTGCTC	60
61	CAGGAGGACT	CTGTGACTCT	GACATGCCAG	GGGGCTCGCA	GCCCTGAGAG	CGACTCCATT	120
121	CAGTGGTTCC	ACAATGGGAA	TCTCATTTCC	ACCCACACGC	AGCCCAGCTA	CAGGTTCAAG	180
181	GCCAACAACA	ATGACAGCGG	GGAGTACACG	TGCCAGACTG	GCCAGACCAG	CCTCAGCGAC	240
241	CCTGTGCATC	TGACTGTGCT	TTCCGAATGG	CTGGTGTCTC	AGACCCCTCA	CCTGGAGTTC	300
301	CAGGAGGGAG	AAACCATCAT	GCTGAGGTGC	CACAGCTGGA	AGGACAAGCC	TCTGGTCAAG	360
361	GTCACATTCT	TCCAGAATGG	AAAATCCAG	AAATTCTCCC	GTTTGGATCC	CACCTTCTCC	420
421	ATCCCACAAG	CAAACCACAG	TCACAGTGGT	GATTACCACT	GCACAGGAAA	CATAGGCTAC	480
481	ACGCTGTTCT	CATCCAAGCC	TGTGACCATC	ACTGTCCAAG	TGCCCTGAAG	CTT	533

SEQ ID NO: 9

>sFcyRIIb

1	CCATGGGGAC	ACCTGCAGCT	CCCCCAAAGG	CTGTGCTGAA	ACTCGAGCCC	CAGTGGATCA	60
61	ACGTGCTCCA	GGAGGACTCT	GTGACTCTGA	CATGCCGGGG	GACTCACAGC	CCTGAGAGCG	120
121	ACTCCATTCA	GTGGTTCCAC	AATGGGAATC	TCATTCCCAC	CCACACGCAG	CCCAGCTACA	180
181	GGTTCAAGGC	CAACAACAAT	GACAGCGGGG	AGTACACGTG	CCAGACTGGC	CAGACCAGCC	240
241	CTCAGCGACC	TGTGCATCTG	ACTGTGCTTT	CTGAGTGGCT	GGTGTCTCCAG	ACCCCTCACC	300
301	TGGAGTTCCA	GGAGGGAGAA	ACCATCGTGC	TGAGGTGCCA	CAGCTGGAAG	GACAAGCCTC	360
361	TGGTCAAGGT	CACATTCTTC	CAGAATGGAA	AATCCAAGAA	ATTTTCCCGT	TCGGATCCCA	420
421	ACTTCTCCAT	CCCACAAGCA	AACCACAGTC	ACAGTGGTGA	TTACCACTGC	ACAGGAAACA	480
481	TAGGCTACAC	GCTGTACTCA	TCCAAGCCTG	TGACCATCAC	TGTCCAAGCT	CCCAGCTCTT	540
541	CACCGATGGG	GATCATTTAG	GCTGTCGAC				569

SEQ ID NO: 10

>sFcyRIII

1	CATATGCGGA	CTGAAGATCT	CCCAAAGGCT	GTGGTGTTC	TGGAGCCTCA	ATGGTACAGC	60
61	GTGCTTGAGA	AGGACAGTGT	GACTCTGAAG	TGCCAGGGAG	CCTACTCCCC	TGAGGACAAT	120
121	TCCACACAGT	GGTTTCACAA	TGAGAGCCTC	ATCTCAAGCC	AGGCCTCGAG	CTACTTCATT	180
181	GACGCTGCCA	CAGTCAACGA	CAGTGGAGCT	TACAGGTGCC	AGACAAACCT	CTCCACCCTC	240
241	AGTGACCCGG	TGCAGCTAGA	AGTCCATATC	GGCTGGCTGT	TGCTCCAGGC	CCCTCGGTGG	300
301	GTGTTCAAGG	AGGAAGACCC	TATTCACCTG	AGGTGTCACA	GCTGGAAGAA	CAGTGTCTG	360
361	CATAAGGTCA	CATATTTACA	GAATGGCAAA	GACAGGAAGT	ATTTTCATCA	TAATTCTGAC	420
421	TTCCACATTC	CAAAAGCCAC	ACTCAAAGAT	AGCGGCTCCT	ACTTCTGCAG	GGGGCTTGTT	480
481	GGGAGTAAAA	ATGTGTCTTC	AGAGACTGTG	AACATCACCA	TCACTCAAGG	TTAAGCTT	538

SEQ ID NO: 11

>sFceRIa

1	CATATGGCAG	TCCCTCAGAA	ACCTAAGGTC	TCCTTGAACC	CTCCATGGAA	TAGAATATTT	60
61	AAAGGAGAGA	ATGTGACTCT	TACATGTAAT	GGGAACAATT	TCTTTGAAGT	CAGTTCCACC	120
121	AAATGGTTCC	ACAATGGCAG	CCTTTTCAGAA	GAGACAAATT	CAAGTTTGAA	TATTGTGAAT	180
181	GCCAAATTTG	AAGACAGTGG	AGAATACAAA	TGTCAGCACC	AACAAGTTAA	TGAGAGTGAA	240
241	CCTGTGTACC	TGGAAGTCTT	CAGTGAAGTG	CTGCTCCTTC	AGGCCTCTGC	TGAGGTGGTG	300
301	ATGGAGGGCC	AGCCCTCTTT	CCTCAGGTGC	CATGGTTGGA	GGAAGTGGGA	TGTGTACAAG	360
361	GTGATCTATT	ATAAGGATGG	TGAAGCTCTC	AAGTACTGGT	ATGAGAACCA	CAACATCTCC	420
421	ATTACAAATG	CCACAGTTGA	AGACAGTGGA	ACCTACTACT	GTACGGGCAA	AGTGTGGCAG	480
481	CTGGACTATG	AGTCTGAGCC	CCTCAACATT	ACTGTAATAA	AAGCTCCGCG	TGAGAAGTAC	540
541	TGGCTACAAT	TTTAGGATCC					560

SEQ ID NO: 12

>sFcεRII

```

1  CATATGGAGT TGCAGGTGTC CAGCGGCTTT GTGTGCAACA CGTGCCCTGA AAAGTGGATC 60
61 AATTTCCAAC GGAAGTGC TA CTACTTCGGC AAGGGCACCA AGCAGTGGGT CCACGCCCGG 120
121 TATGCCCTGTG ACGACATGGA AGGGCAGCTG GTCAGCATCC ACAGCCCGGA GGAGCAGGAC 180
181 TTCCTGACCA AGCATGCCAG CCACACCGGC TCCTGGATTG GCCTTCGGAA CTGGACCTG 240
241 AAGGGGGAGT TTATCTGGGT GGATGGGAGC CACGTGGACT ACAGCAACTG GGCTCCAGGG 300
301 GAGCCCACCA GCCGGAGCCA GGGCGAGGAC TGCCTGATGA TGCGGGGCTC CGGTCTGCTGG 360
361 AACGACGCCCT TCTGCGACCG TAAGCTGGGC GCCTGGGTGT GCGACCGGCT GGCCACATGC 420
421 ACGCCGCCAG CCAGCGAAGG TTCCGCGGAG TCCATGGGAC CTGATTCAAG ACCAGACCCT 480
481 GACGGCCGCC TGCCACCCC CTCTGCCCTT CTCCACTCTT GAGCATGGAT CC 532

```

SEQ ID NO:13

human FcγRIIb2

```

1  ggctgtgact gctgtgctct gggcgccact cgctccaggg agtgatggga atcctgtcat
61  ttttacctgt ccttgccact gagagtgact gggctgactg caagtcccc cagccttggg
121 gtcatatgct tctgtggaca gctgtgctat tcctggctcc tgttgctggg acacctgcag
181 ctccccaaa ggctgtgctg aaactcgagc cccagtggat caactgtctc caggaggact
241 ctgtgactct gacatgccgg gggactcaca gccctgagag cgactccatt cagtggttcc
301 acaatgggaa tctcattccc acccacacgc agcccagcta caggttcaag gccacaaca
361 atgacagcgg ggagtacacg tgccagactg gccagaccag cctcagcgac cctgtgcatc
421 tgacagtgtc ttctgagtgg ctgggtgctcc agaccctca cctggagtcc caggagggag
481 aaaccatcgt gctgaggtgc cacagctgga aggacaagcc tctgggtcaag gtcacattct
541 tccagaatgg aaaatccaag aaattttccc gttcggatcc caacttctcc atcccacaag
601 caaaccacag tcacagtggg gattaccatt gcacaggaaa cataggctac acgtgtact
661 catccaagcc tgtgaccatc actgtccaag ctcccagctc ttcaccgatg gggatcattg
721 tggctgtggg cactgggatt gctgtagctg ccattgttgc tgctgtagtg gccttgatct
781 actgcaggaa aaagcggatt tcagccaatc ccactaatcc tgatgaggct gacaaagttg
841 gggctgagaa cacaatcacc tattcacttc tcatgcaccc ggatgctctg gaagagcctg
901 atgaccagaa ccgtatttag tctccattgt cttgcattgg gatttgagaa gaaatcagag
961 aggggaagatc tgggtatttc tggcctaaat tccccttggg gaggacaggg agatgctgca
1021 gttccaaaag agaaggtttc ttccagagtc atctacctga gtccatgaag tccctgtcct
1081 gaaagccaca gacaatatgg tcccaaatgc ccgactgcac cttctgtgct tcagctcttc
1141 ttgacatcaa ggctcttccg ttccacatcc acacagccaa tccaattaat caaaccactg
1201 ttattaacag ataatagcaa cttgggaaat gcttatgtta caggttacgt gagaacaatc
1261 atgtaaatct atatgatttc agaaatgtta aatagacta acctctacca gcacattaaa
1321 agtgattgtt tctgggtgat aaaattattg atgattttta ttttcttata ttttctataa
1381 agatcatata ttacttttat aataaaacat tataaaaaac

```

SEQ ID NO:14

human FcεRIα

```
1   agatctcagc acagtaagca ccaggagtcc atgaagaaga tggctcctgc catggaatcc
61  cctactctac tgtgtgtagc cttactgttc ttcgctccag atggcggtgtt agcagtcacct
121 cagaaaccta aggtctcctt gaacctctca tggaaatagaa tatttaaagg agagaatgtg
181 actcttacat gtaatgggaa caatttcttt gaagtcagtt ccaccaaag gttccacaat
241 ggcagccttt cagaagagac aaattcaagt ttgaatattg tgaatgccaa atttgaagac
301 agtgggagaat acaaatgtca gcaccaacaa gttaatgaga gtgaacctgt gtacctggaa
361 gtcttcagtg actggctgct ccttcaggcc tctgctgagg tggatgatgga gggccagccc
421 ctcttcctca ggtgccatgg ttggaggaac tgggatgtgt acaaggatgat ctattataag
481 gatgggtgaag ctctcaagta ctggtatgag aaccacaaca tctccattac aaatgccaca
541 gttgaagaca gtggaacctc ctactgtacg ggcaaagtgt ggcagctgga ctatgagtct
601 gagccccctc acattactgt aataaaaagct ccgcgtgaga agtactggct acaatttttt
661 atcccattgt tgggtggtgat tctgtttgct gtggacacag gattatttat ctcaactcag
721 cagcaggtca catttctctt gaagattaag agaaccagga aaggcttcag acttctgaac
781 ccacatccta agccaaaccc caaaaacaac tgatataatt aactcaagaa atatttgcaa
841 cattagtttt tttccagcat cagcaattgc tactcaattg tcaaacacag cttgcaatat
901 acatagaaac gtctgtgctc aaggatttat agaaatgctt cattaaactg agtgaaactg
961 attaagtggc atgtaatagt aagtgtcaa ttaacattgg ttgaataaat gagagaatga
1021 atagattcat ttattagcat ttgtaaaaga gatgttcaat ttagatct
```

SEQ ID NO:15

human mRNA for high affinity Fc receptor (FcγRI)

```
1   gacagatttc actgctccca ccagcttgga gacaacatgt ggttcttgac aactctgctc
61  ctttgggttc cagttgatgg gcaagtggac accacaaagg cagtgatctc tttgcagcct
121 ccatgggtca gcggtgtcca agaggaaacc gtaaccttgc actgtgaggt gctccatctg
181 cctgggagca gctctacaca gtggtttctc aatggcacag cactcagac ctcgaccccc
241 agctacagaa tcacctctgc cagtgtcaat gacagtgggtg aatacaggtg ccagagaggt
301 ctctcagggc gaagtgaccc catacagctg gaaatccaca gaggctggct actactgcag
361 gtctccagca gagtcttcac ggaaggagaa cctctggcct tgagggtgtca tgcgtggaag
421 gataagctgg tgtacaatgt gctttactat cgaaatggca aagcctttaa gtttttccac
481 tggaattcta acctcaccat tctgaaaacc aacataagtc acaatggcac ctaccattgc
541 tcaggcatgg gaaagcatcg ctacacatca gcaggaatat ctgtcactgt gaaagagcta
601 tttccagctc cagtgtgaa tgcatctgtg acatccccac tctggagggg gaatctggtc
661 accctgagct gtgaaacaaa gttgctcttg cagaggcctg gtttgcagct ttactttctc
721 ttctacatgg gcagcaagac cctgcgaggc aggaacacat cctctgaata ccaaatacta
781 actgctagaa gagaagactc tgggttatac tgggtgcgagg ctgccacaga ggatggaaat
841 gtccttaagc gcagccctga gttggagctt caagtgtctg gcctccagtt accaactcct
901 gtctggtttc atgtcctttt ctatctggca gtgggaataa tgtttttagt gaacactgtt
961 ctctgggtga caatacgtaa agaactgaaa agaaagaaaa agtgggattt agaaatctct
1021 ttggattctg gtcatgagaa gaaggtaact tccagccttc aagaagacag acatttagaa
1081 gaagagctga aatgtcagga acaaaaagaa gaacagctgc aggaaggggt gcaccggaag
1141 gagccccagg gggccacgta gcagcggctc agtgggtggc catcgatctg gaccgtcccc
1201 tgcccacttg ctccccgtga gcaactgcgt caaacatcca aaagttcaac aacaccagaa
1261 ctgtgtgtct catggtatgt aactcttaaa gcaaataaat gaactgactt caaaaaaaaa
1321 a
```

SEQ ID NO:16

human FcγRIIa

```
1      cccaaatgtc tcagaatgta tgtcccagaa acctgtggct gcttcaacca ttgacagttt
61     tgctgctgct ggcttctgca gacagtcaag ctgcagctcc cccaaaggct gtgctgaaac
121    ttgagccccc gtggatcaac gtgctccagg aggactctgt gactctgaca tgccaggggg
181    ctgcagccc tgagagcgac tccattcagt ggttccacaa tgggaatctc attcccaccc
241    acacgcagcc cagctacagg ttcaaggcca acaacaatga cagcggggag tacacgtgcc
301    agactggcca gaccagcctc agcgaccctg tgcattctgac tgtgctttcc gaatggctgg
361    tgctccagac ccctcacctg gagttccagg agggagaaaac catcatgctg aggtgccaca
421    gctggaagga caagcctctg gtcaagggtca cttctttcca gaatggaaaa tcccagaaat
481    tctcccgttt ggatcccacc ttctccatcc cacaagcaaa ccacagtcac agtgggtgatt
541    accactgcac aggaaacata ggctacacgc tgttctcatc caagcctgtg accatcactg
601    tccaagtgcc cagcatgggc agctcttcac caatggggat cattgtggct gtggtcattg
661    cgactgctgt agcagccatt gttgctgctg tagtggcctt gatctactgc aggaaaaagc
721    ggatttcagc caattccact gatcctgtga aggctgcca atttgagcca cctggacgtc
781    aaatgattgc catcagaaag agacaacttg aagaaaccaa caatgactat gaaacagctg
841    acggcgggcta catgactctg aaccccaggg cacctactga cgatgataaa aacatctacc
901    tgactcttcc tcccacgac catgtcaaca gtaataacta aagagtaacg ttatgccatg
961    tggtcatact ctgagcttgc tgatggatga caaaaagagg ggaattgtta aagggaaatt
1021   taaatggaga ctggaaaaat cctgagcaaa caaaaccacc tggcccttag aaatagcttt
1081   aactttgctt aaactacaaa cacaagcaaa acttcacggg gtcatactac atacaagcat
1141   aagcaaaact taacttggat ctttctgggt aaatgcttat gttagaaata agacaacccc
1201   agccaatcac aagcagccta ctaacatata attaggtgac tagggacttt ctaagaagat
1261   acctaccccc aaaaaacaat tatgtaattg aaaaccaacc gattgccttt attttgcttc
1321   cacattttcc caataaatac ttgcctgtga ctttttgcca ctggaacact aaacttcatg
1381   aattgogcct cagatttttc ctttaacatc tttttttttt ttgacagagt ctcaatctgt
1441   taccagggct ggagtgcagt ggtgctatct tggtcactg caaacccgcc tcccaggttt
1501   aagcgattct tatgcctcag cctcccagta gctgggatta gaggcattgt ccatcatacc
1561   cagctaattt ttgtattttt ttttttttat ttttagtaga gacagggttt cgcaatgttg
1621   gccaggccga tctcgaactt ctggcctcta gcgatctgcc cgctcggcc tcccaaagtg
1681   ctgggatgac cgcattcagcc ccaatgtcca gcctctttaa catcttcttt cctatgcctt
1741   ctctgtggat cctactgct ggtttctgcc ttctccatgc tgagaacaaa atcacctatt
1801   cactgcttat gcagtcggaa gctccagaag acaaaagagc ccaattacca gaaccacatt
1861   aagtctccat tgttttgctt tgggatttga gaagagaatt agagaggtga ggatctggta
1921   tttcctggac taaattccct tggggaagac gaagggatgc tgcagttcca aaagagaagg
1981   actcttcag agtcatctac ctgagtcca aagctccctg tctgaaagc cacagacaat
2041   atgggtcccaa atgactgact gcacctctg tgctcagcc gttcttgaca tcaagaatct
2101   tctgttccac atccacacag ccaatacaat tagtcaaacc actgttatta acagatgtag
2161   caacatgaga aacgcttatg ttacagggtta catgagagca atcatgtaag tctatatgac
2221   ttcagaaatg ttaaaataga ctaacctcta acaacaaatt aaaagtgatt gtttcaagg
2281   gatgcaatta ttgatgacct attttatttt tctataatga tcatatatta cctttgtaat
2341   aaaacattat aacaaaaac
```

SEQ ID NO:17

human FcγRIII

```
1      tcttttgggtga cttgtccact ccagtgtggc atcatgtggc agctgctcct cccaactgct
61     ctgctacttc tagtttcagc tggcatgcg actgaagatc tcccaaaggc tgtggtgttc
121    ctggagcctc aatggtacag cgtgcttgag aaggacagtg tgactctgaa gtgccaggga
181    gcctactccc ctgaggacaa ttccacacag tggtttcaca atgagagcct catctcaagc
241    caggcctcga gctacttcat tgacgtgcc acagtcaacg acagtggaga gtacaggtgc
301    cagacaaacc tctccaccct cagtgaccog gtgcagctag aagtccatat cggctggctg
361    ttgctccagg ccctcggtg ggtgttcaag gaggaagacc ctattcacct gaggtgtcac
421    agctggaaga aactgctct gcataaggtc acatatttac agaatggcaa agacaggaag
481    tattttcate ataattctga ctccacatt ccaaaagcca cactcaaaga tagcggtccc
541    tacttctgca gggggcttgt tgggagtaaa aatgtgtctt cagagactgt gaacatcacc
601    atcactcaag gtttggcagt gtcaaccatc tcattcattct ctccacctgg gtaccaagtc
661    tctttctgct tggatggtt actccttttt gcagtggaca caggactata tttctctgtg
721    aagacaaaca tttgaagctc aacaagagac tggaaggacc ataaacttaa atggagaaag
781    gacctcaag acaaatgacc cccatcccat gggagtaata agagcagtgg cagcagcatc
841    tctgaacatt tctctggatt tgcaacccca tcctcctcag gcctctc
```

SEQ ID NO: 18

human FcεRII

```
1 ctctgctta aacctctgtc tctgacggtc cctgccaatc gctctggctc
accccaacac
61 actaggagga cagacacagg ctccaaactc cactaagtga ccagagctgt gattgtgccc
121 gctgagtggg ctgcgttggt agggagtggg tgctccatca tcgggagaat ccaagcagga
181 ccgccatgga ggaagggtcaa tattcagaga tcgaggagct tcccaggagg cgggtgtgca
241 ggcgtgggac tcagatcgtg ctgctggggc tggtgaccgc cgctctgtgg gctgggctgc
301 tgactctgct tctcctgtgg cactggggaca ccacacagag tctaaaacag ctggaagaga
361 gggctgcccc gaacgtctct caagtttcca agaacttgga aagccaccac ggtgaccaga
421 tggcgcgaaa atcccagtc acgcagattt cacaggaact ggaggaactt cgagctgaac
481 agcagagatt gaaatctcag gacttggagc tgcctggaa cctgaacggg cttcaagcag
541 atctgagcag cttcaagtcc caggaattga acgagaggaa cgaagcttca gatttgctgg
601 aaagactccg ggaggagggtg acaaagctaa ggatggagtt gcaggtgtcc agcggctttg
661 tgtgcaacac gtgccctgaa aagtggatca atttccaacg gaagtgtac tacttcggca
721 agggcaccaa gcagtgggtc cagccccggt atgcctgtga cgacatggaa gggcagctgg
781 tcagcatcca cagccccgag gagcaggact tcctgaccaa gcatgccagc cacaccggct
841 cctggattgg ccttcggaac ttggacctga agggagagtt tatctgggtg gatgggagcc
901 atgtggacta cagcaactgg gctccagggg agcccaccag ccggagccag ggcgaggact
961 gcgtgatgat gcggggctcc ggtcgctgga acgacgcctt ctgcgaccgt aagctgggcg
1021 cctgggtgtg cgaccggctg gccacatgca cgccgccagc cagcgaaggt tccgcgaggt
1081 ccatgggacc tgattcaaga ccagaccctg acggccgcct gccaccccc tctgcccctc
1141 tccactcttg agcatggata cagccaggcc cagagcaaga ccctgaagac ccccaaccac
1201 ggcctaaaag cctctttgtg gctgaaaggt ccctgtgaca ttttctgcca cccaaacgga
1261 ggcagctgac acatctcccc ctctctatg gcccctgcct tcccaggagt acacccaac
1321 agcacctct ccagatggga gtgcccccaa cagcacctc tccagatgag agtacacccc
1381 aacagcacc cctccagatg cagccccatc tcctcagcac cccaggacct gagtatcccc
1441 agctcagggt gtgagtcctc ctgtccagcc tgcataata aaatggggca gtgatggcct
1501 ccc
```

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/09440

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 31-38
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Int. Patent Application No
PCT/EP 99/09440

Form PCT/SA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/09440

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 623 053 A (LOUIS N. GASTINEL ET AL.) 22 April 1997 (1997-04-22)	1,4,6, 8-13, 39-42
Y	column 5, line 60 -column 8, line 67; examples	5,7,24, 26,28-30
X	WO 96 40199 A (UNIVERSITY OF PENNSYLVANIA) 19 December 1996 (1996-12-19)	1,2,4,6, 8-16, 19-22
Y	page 22, line 24 -page 24, line 14; claims 13-16,36-39; examples I,II	5,7,24, 26,28-30
X	WO 95 09002 A (UNIVERSITY OF PENNSYLVANIA) 6 April 1995 (1995-04-06)	1,2,4,6, 8-13,16, 21,39,40
Y	page 15, line 4 -page 16, line 22; claims 28-31; examples I,II	5,7,24, 26,28-30
X	EP 0 791 653 A (SCHERING BIOTECH CORPORATION) 27 August 1997 (1997-08-27)	1,2,4,6, 8-11,21, 22
Y	column 5, line 56 -column 10, line 1; example III	5,7,24, 26,28-30
X	JÉRÔME GALON ET AL.: "Ligands and biological activities of soluble Fcγgamma receptors" IMMUNOLOGY LETTERS, vol. 44, January 1995 (1995-01), pages 175-181, XP000574018	1-4,6, 8-13,15, 16,19-22
Y	page 175, right-hand column, last paragraph -page 177, left-hand column, paragraph 1 page 179, right-hand column, paragraph 3 -page 180, right-hand column, paragraph 3	5,7,24, 26,28-30
X	EP 0 321 842 A (KISHIMOTO, TADAMITSU) 28 June 1989 (1989-06-28)	1,2, 4-19,21, 22
Y	column 2, line 10 -column 9, line 43; figure 4; examples B,,1-3,6,,7	24,26, 28,30
	-/-	

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/EP 99/09440

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 259 615 A (KISHIMOTO, TADAMITSU) 16 March 1988 (1988-03-16)	1,2, 4-15, 17-19, 21,22, 24,26, 28-30
Y	page 2, line 1 -page 37, line 13	
Y	JANET M. ALLEN ET AL.: "Isolation and expression of functional high-affinity Fc receptor complementary DNAs" JOURNAL OF CRYSTAL GROWTH, vol. 93, no. 1-4, November 1988 (1988-11) - December 1988 (1988-12), pages 378-381, XP000002750 Amsterdam, NL abstract; figure 4	5,7
Y	WILHELM P. BURMEISTER ET AL.: "Crystal structure at 2.2A resolution of the MHC-related neonatal Fc receptor" NATURE, vol. 372, no. 6504, 24 November 1994 (1994-11-24), pages 336-343, XP002135452 LONDON GB the whole document	24,26, 28-30
P,X	WO 99 05271 A (GOULD, HANNAH ET AL.) 4 February 1999 (1999-02-04) page 4, line 6 - line 19 page 5, line 22 -page 6, line 2 page 7, line 22 -page 8, line 23 page 10, line 31 -page 11, line 31	1,2,4,6, 8-15,21, 22,39

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 99 09440

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 31-38

Present claims 31-38 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is not to be found, however, for any specific example of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search has been carried out for claims 31-38.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In. ational Application No

PCT/EP 99/09440

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
FR 2739560	A	11-04-1997	AU 7303596 A WO 9713524 A	30-04-1997 17-04-1997
EP 614978	A	14-09-1994	FR 2702481 A CA 2118558 A JP 7149800 A	16-09-1994 10-09-1994 13-06-1995
US 5623053	A	22-04-1997	NONE	
WO 9640199	A	19-12-1996	AU 6386996 A CA 2223402 A EP 0831875 A JP 11507824 T US 5858981 A	30-12-1996 19-12-1996 01-04-1998 13-07-1999 12-01-1999
WO 9509002	A	06-04-1995	AU 701919 B AU 7924494 A CA 2172392 A EP 0723455 A JP 9506072 T US 5858981 A	11-02-1999 18-04-1995 06-04-1995 31-07-1996 17-06-1997 12-01-1999
EP 791653	A	27-08-1997	AU 3740089 A EP 0343950 A EP 0449828 A JP 2657221 B JP 3501484 T KR 149012 B WO 8911490 A US 5976831 A US 5767077 A CA 2000355 A	12-12-1989 29-11-1989 09-10-1991 24-09-1997 04-04-1991 17-08-1998 30-11-1989 02-11-1999 16-06-1998 19-07-1990
EP 321842	A	28-06-1989	EP 0321601 A EP 0324879 A AU 2738088 A DK 712488 A FI 885873 A HU 50498 A JP 2000443 A NO 885687 A PT 89299 A ZA 8809506 A	28-06-1989 26-07-1989 13-07-1989 23-06-1989 23-06-1989 28-02-1990 05-01-1990 23-06-1989 29-12-1989 29-08-1990
EP 259615	A	16-03-1988	EP 0257114 A EP 0286700 A AU 7716587 A DD 263538 C DK 434287 A EP 0258489 A EP 0258492 A FI 873614 A HU 44620 A JP 1027496 A NO 873512 A NZ 221501 A PT 85560 A,B SU 1727533 A	02-03-1988 19-10-1988 19-05-1988 27-09-1989 22-02-1988 09-03-1988 09-03-1988 22-02-1988 28-03-1988 30-01-1989 22-02-1988 28-08-1990 01-09-1987 15-04-1992

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/EP 99/09440

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 259615 A		ZA 8706168 A	26-04-1989
WO 9905271 A	04-02-1999	AU 8455598 A	16-02-1999